IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy

IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy

DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company will host a key opinion leader (KOL) webcast on the treatment options in ovarian cancer and competitive landscape within the disease state on Thursday, December 3, 2020 at 8.00am Eastern Time.

The webcast will feature presentations by KOLs Oliver Dorigo, MD, PhD and Jeannine Villella, DO, FACOG, FACS who will discuss the treatment options in ovarian cancer and competitive landscape within the disease state. The KOLs will also provide an update on the ongoing Phase 2 trial with IMV’s novel T cell therapy in patients with advanced ovarian cancer, along with insights about the patients’ experience. Drs. Dorigo and Villella will be available to answer questions from financial analysts following the formal presentation.

IMV management will discuss trial results and their significance to DPX, the company’s delivery platform, as well its outlook on next steps.

To register for the webcast, please click here. A webcast of the presentation will be available under “Events, Webcasts and Presentations” in the investors section of IMV’s website and a replay will be available approximately one hour after the presentation. Afterwards, the replay will be available for approximately 30 days. Financial analysts are welcome to ask questions during the live Q&A and are invited to submit their request via email.

About the KOLs

Dr. Oliver Dorigo is the director and associate professor of the division of gynecologic oncology and the director of the gynecologic clinical care program at the Women’s Cancer Center at Stanford University. He is also director of the Mary Lake Polan Gynecologic Oncology Research Laboratory. Dr. Dorigo received his MD from the University of Heidelberg Medical School in Germany. He did a residency in obstetrics and gynecology at the University of Munich, followed by a research fellowship in cancer gene therapy at the Sidney Kimmel Cancer Center in San Diego. He completed his PhD in molecular biology at University of California, Los Angeles, and a clinical fellowship in gynecologic oncology at UCLA/Cedars Sinai Medical Center. Dr. Dorigo was an assistant professor at UCLA until he joined the Stanford faculty in 2013.

Dr. Jeannine Villella obtained her medical degree from New York College of Osteopathic Medicine in Old Westbury, New York and completed her residency training in Obstetrics and Gynecology at Winthrop University Hospital. Thereafter, Dr. Villella was granted a 2-year Henrietta Milstein Fellowship at Columbia University College of Physicians & Surgeons. As part of the division of gynecologic oncology, she performed research in the role of angiogenesis in ovarian cancer and was involved in the care of gynecologic oncology patients. She then completed a 3-year subspecialty fellowship in Gynecologic Oncology at Roswell Park Cancer Institute, where she expanded her research interests into immune response to malignancy and cancer immunotherapy. She has been granted a Winthrop University Hospital Pilot Grant to pursue her research interests in genetic polymorphisms in indoleamine 2, 3- dioxygenase and the effect on ovarian cancer outcomes. Her future goals include having ovarian cancer vaccine clinical trials available at Winthrop University Hospital. She also serves on the Society of Gynecologic Oncologists Clinical Practice Committee and the Gynecologic Oncology Group Vaccine Committee. Dr. Villella is board certified in Obstetrics & Gynecology and Gynecologic Oncology. She currently holds the title Associate Director of Gynecologic Oncology at Winthrop University Hospital and Assistant Professor of Stony Brook School of Medicine. She is the Principal Investigator for the Gynecologic Oncology Group Clinical Trials at Winthrop University Hospital. She also serves on the Society of Gynecologic Oncologists Clinical Practice Committee. She is also an active member of the research organization Society of Gynecologic Investigation.

About the DeCidE Study

“DeCidE” is a Phase 2 multicenter, randomized, open-label study to evaluate the safety and effectiveness of DPX-Survivac with intermittent low dose cyclophosphamide (CPA). This phase 2 arm enrolled 22 patients with recurrent, advanced platinum-sensitive and –resistant ovarian cancer. The trial is active but not recruiting. Patients received 2 subcutaneous injections of DPX-Survivac 3 weeks apart and every eight weeks thereafter, and intermittent low dose CPA one week on and one week off for up to 1 year. Paired tumor biopsies were performed prior to treatment and on treatment.

Primary endpoints of this study are overall response rate, disease control rate and safety. Secondary endpoints include cell mediated immunity, immune cell infiltration in paired biopsy samples, duration of response, time to progression, overall survival and biomarker analyses.

About DPX-Survivac

DPX-Survivac is the lead candidate in IMV’s new class of immunotherapy that generates targeted and sustained cancer cell killing capabilities in vivo. Treatments with the DPX-Survivac T cell therapy have demonstrated a favorable safety profile across all clinical studies.

IMV’s T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in IMV’s proprietary delivery platform (DPX). IMV’s lead compound is designed to generate a sustained cytotoxic T cell response against cancer cells presenting survivin peptides on their surface.

Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen, is broadly over-expressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to chemotherapies. IMV has identified over 20 cancer indications in which survivin can be targeted by DPX-Survivac.

DPX-Survivac has received Fast Track designation from the U.S. Food and Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as Orphan Drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary delivery platform (DPX). This patented technology leverages a novel mechanism of action that enables the activation of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing DPX-Survivac in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19. Visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

IMV Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, the potential impacts of biomarkers when treating cancer; the potential for using DPX-Survivac to treat different types of cancers; and the results and timing of expected results from the Corporation’s various DPX-Survivac’s studies. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful design and completion of clinical trials and the receipt and timely receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV Inc.

O: (902) 492-1819 ext : 1042

M: (514) 617-9481 E: [email protected]

Irina Koffler, Managing Director, LifeSci Advisors

O: (646) 970-4681

M: (917) 734-7387

E: [email protected]

Media

Delphine Davan, Director of Communications, IMV Inc.

M: (514) 968 1046

E: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Oncology Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology

MEDIA:

OncXerna Therapeutics to Participate at the Piper Sandler Virtual Healthcare Conference

WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to predict patient responses for potentially first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will participate at the Piper Sandler Virtual Healthcare Conference taking place November 30-December 3, 2020.

A
bout OncXerna Therapeutics

OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant, RNA-based biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes. For more information on OncXerna, please visit: oncxerna.com/

A
bout OncXerna’s RNA-based Biomarker Platform

Existing precision medicines target only approximately 10% of cancers—those with gene mutations or oncogenic drivers for a small number of genes. Using its proprietary biomarker platform, OncXerna is leveraging the company’s deep understanding of tumor biology at the RNA level to identify the dominant biology underlying a patient’s cancer. OncXerna’s first biomarker panel is specific to the tumor microenvironment (TME Panel-1). Initial results from TME Panel-1 reveal 4 different dominant biologies, demonstrating the presence of specific patient subgroups and their predictive value in responding to treatment. OncXerna is further optimizing the biomarker platform’s tumor microenvironment panel through multiple research collaborations, including a collaboration with Moffitt Cancer Center.

A
bout Bavituximab

Bavituximab is an investigational antibody that reverses immune suppression by inhibiting phosphatidylserine (PS) signaling and is currently in Phase 2 clinical trials to treat a specific subset of patients with advanced gastric cancer to improve their response to anti-PD-1 treatment. The mechanism of action of bavituximab is to block tumor immune suppression signaling from PS to multiple immune cell receptor families (e.g., TIMs and TAMs). The dominant biology targeted by bavituximab may be relevant for patients with many types of solid tumors whose immune systems are too suppressed to benefit from currently available immune oncology therapies. OncXerna’s clinical trials currently combine bavituximab with KEYTRUDA® to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors. Bavituximab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced gastric cancer.

A
bout Navicixizumab

Navicixizumab is an investigational anti-DLL4/VEGF bispecific antibody that has demonstrated antitumor activity in patients who have progressed on Avastin (bevacizumab) in a Phase 1a/b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or prior treatment with Avastin. OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways. Navicixizumab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Investor and Media
Contact:

Ashley R. Robinson
LifeSci Partners, LLC
[email protected]

Timbercreek Financial Announces 2020 Third Quarter Results

Company also announces changes to Board of Directors

TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) announced today its financial results for the three months and nine months ended September 30, 2020 (“Q3 2020”).


Q3 2020 Highlights

  • Portfolio continues to perform well through the COVID-19 pandemic with no material increase in delinquencies
     
  • Generated $0.18 in distributable income per share and $0.17 adjusted net income per share as well as delivered a 98.3% distributable income payout ratio and a 102.5% adjusted net income payout ratio.
     
  • Funded $89.4M on new and existing mortgages versus repayments of $145.8M.  This resulted in a reduction of net mortgage investments to $1,153.2M in Q3 2020.  The increase in repayments resulted in a Q3 turnover ratio of 12.3% versus 6.4% in Q2 and is a positive sign of increased market activity that will provide capital for new investment opportunities.  Of note, the majority of these repayments (71%) occurred in September.
     
  • Maintained conservative portfolio risk position focused on income-producing commercial real estate
    ° 90.4% of mortgage investment portfolio are first mortgages
    ° 84.1% of mortgage investment portfolio is invested in cash-flowing properties
    ° 68.2% weighted average loan-to-value
    ° 7.2% quarterly weighted average interest rate on net mortgage investment
     
  • Delivered adjusted net income and comprehensive income of $13.6 million and distributable income of $14.2 million
     
  • Paid $14.0 million in dividends to shareholders

“Our mortgage portfolio continued to perform solidly in the third quarter, with collection rates remaining high and trending in line with historical norms,” said Blair Tamblyn, Chief Executive Officer of Timbercreek Financial. “This performance underscores the benefit of our emphasis on durable, income-generating assets and our conservative portfolio positioning. Importantly, we delivered distributable income in line with our expectations. New investment activity was lower in the quarter as transaction volumes declined across the industry. We had a material volume of repayments, which, when combined with a larger debt facility, will enable us to capitalize on new investment opportunities in the market. We have already seen an uptick in transaction activity in the current quarter.”


Quarterly Comparison


$ millions
Q3 2020     Q3 2019   Q2 2020
             
Net Mortgage Investments $ 1,153.2       $ 1,174.1     $ 1,210.3  
Enhanced Return Portfolio Investments $ 93.6       $ 103.0     $ 82.6  
             
Net Investment Income $ 24.1       $ 24.7     $ 22.0  
Income from Operations $ 20.2       $ 21.3     $ 18.2  
Net Income and comprehensive Income $ 14.4       $ 13.9     $ 11.7  
–Adjusted Net Income and comprehensive Income $ 13.6       $ 13.9     $ 11.5  
Distributable Income $ 14.2       $ 15.9     $ 14.8  
Dividends to Shareholders $ 14.0       $ 14.3     $ 14.2  
             

$ per share
Q3 2020     Q3 2019   Q2 2020
             
Dividends per share $ 0.17       $ 0.17     $ 0.17  
Distributable Income per share $ 0.18       $ 0.19     $ 0.18  
Earnings per share $ 0.18       $ 0.17     $ 0.14  
–Adjusted Earnings per share $ 0.17       $ 0.17     $ 0.14  
             
Payout Ratio on Distributable Income 98.3 %     90.2 %   95.7 %
Payout Ratio on Earnings per share 96.7 %     103.0 %   120.5 %
Payout Ratio on Adjusted Earnings per share 102.5 %     103.0 %   122.6 %
             

Net Mortgage Investments
Q3 2020     Q3 2019   Q2 2020
             
Weighted Average Loan-to-Value 68.2 %     67.8 %   68.7 %
Weighted Average Remaining Term to Maturity 1.1 yr     1.1 yr   1.3 yr
First Mortgages 90.4 %     92.8 %   92.1 %
Cash-Flowing Properties 84.1 %     87.4 %   85.8 %
Rental Apartments 50.0 %     46.5 %   51.6 %
Floating Rate Loans with rate floors (at quarter end) 77.3 %     58.0 %   75.1 %
             
Weighted Average Interest Rate            
For the quarter ended 7.2 %     7.3 %   7.1 %
Weighted Average Lender Fee            
New and Renewed 0.7 %     0.9 %   0.7 %
New Net Mortgage Investment Only 1.2 %     1.2 %   1.1 %




Board of Director Changes


The Company also announced the following changes to its Board of Directors, which reflect the recently announced evolution of Timbercreek Asset Management (“Timbercreek”).

  • Scott Rowland, Chief Investment Officer of Timbercreek, joins the Board as a director. Mr. Rowland is responsible for the development of investment strategies and the overall performance of Timbercreek’s portfolios, and oversees the company’s investment team. Mr. Rowland has over 20 years of industry experience with roles including the Co-Head of Debt Strategies for Fiera Properties and the Managing Director for Blackstone’s debt business in Canada. During a 19-year career at GE Capital, Mr. Rowland held a variety of roles including credit underwriting, Asset Management Leader, Originations Leader and the Managing Director for Real Estate in Canada.   
  • Steven Scott, a long-time independent director of the Company, has reached an agreement in principle to acquire an ownership position in Timbercreek, and will become a non-independent director as a result. To ensure the appropriate ratio of independent directors, Ugo Bizzarri, has agreed to resign from the Board of Directors.    
  • Amar Bhalla joins the Board as an independent director. Mr. Amar Bhalla is a principal at the Amdev Property Group, a private real estate company that owns and manages a portfolio of apartment buildings, commercial sites, and development projects in the GTA. He has over 20 years of experience in the acquisition, repositioning and redevelopment of GTA-based real estate across asset classes. Mr. Bhalla serves on the boards of several TSX and TSX-V listed businesses, including acting as Chair of Dream Impact Trust. Mr. Bhalla is a CFA charterholder and a member of the Institute of Corporate Directors.
  • Cameron Goodnough, who is transitioning the Timbercreek CEO role to Blair Tamblyn, will also no longer serve on the Board.

“We’re thrilled to add Scott and Amar as new directors. Given Scott’s enhanced role with Timbercreek as CIO, we look forward to his direct involvement with the Board. Amar’s extensive experience in value-add real estate strategies make him an ideal addition and an excellent complement to the skill-sets of the existing directors,” added Mr. Tamblyn. “On behalf of the Board, I would like to thank Ugo and Cam for their significant contributions to the success of Timbercreek Financial over many years. We look forward to collaborating with them as they continue to grow their direct real estate and public securities business under the Hazelview brand.” 

Quarterly Conference Call

Interested parties are invited to participate in a conference call with management on Monday, November 16, 2020 1:00 p.m. (EST) which will be followed by a question and answer period with analysts. To join the call:


https://timbercreekfinancial.adobeconnect.com/tfq32020/


Participant Toll Free Dial-In Number: (855) 223-7310
Participant International Dial-In Number: (647) 788-4930
Conference ID Number: 4282428

The playback of the conference call will also be available on www.timbercreekfinancial.com following the call.

About the Company

Timbercreek Financial is a leading non-bank, commercial real estate lender providing shorter-duration, structured financing solutions to commercial real estate professionals. Our sophisticated, service-oriented approach allows us to meet the needs of borrowers, including faster execution and more flexible terms that are not typically provided by Canadian financial institutions. By employing thorough underwriting, active management and strong governance, we are able to meet these needs while generating strong risk-adjusted yields for investors. Further information is available on our website, www.timbercreekfinancial.com.

Non-IFRS Measures

The Company prepares and releases financial statements in accordance with IFRS. As a complement to results provided in accordance with IFRS, the Company discloses certain financial measures not recognized under IFRS and that do not have standard meanings prescribed by IFRS (collectively the “non-IFRS measures”). These non-IFRS measures are further described in Management’s Discussion and Analysis (“MD&A”) available on SEDAR. The Company has presented such non-IFRS measures because the Manager believes they are relevant measures of the Company’s ability to earn and distribute cash dividends to shareholders and to evaluate its performance. The following non-IFRS financial measures should not be construed as alternatives to total net income and comprehensive income or cash flows from operating activities as determined in accordance with IFRS as indicators of the Company’s performance.

Certain statements contained in this news release may contain projections and “forward looking statements” within the meaning of that phrase under Canadian securities laws. When used in this news release, the words “may”, “would”, “should”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “objective” and similar expressions may be used to identify forward looking statements. By their nature, forward looking statements reflect the Company’s current views, beliefs, assumptions and intentions and are subject to certain risks and uncertainties, known and unknown, including, without limitation, those risks disclosed in the Company’s public filings. Many factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by these forward looking statements. The Company does not intend to nor assumes any obligation to update these forward looking statements whether as a result of new information, plans, events or otherwise, unless required by law.

SOURCE: Timbercreek Financial

For further information, please contact:
Timbercreek Financial

Blair Tamblyn
Chief Executive Officer
[email protected]

Tracy Johnston
Chief Financial Officer
[email protected]



BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial

—Data presented at 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)—

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented new clinical data that further evaluates the attack rate reductions, patient satisfaction and quality of life of hereditary angioedema (HAE) patients in the APeX-2 trial over 48 weeks. Berotralstat is an investigational treatment for the prevention of attacks in patients with HAE.

The data from three abstracts, including a Distinguished Industry Oral Abstract, are being presented at the 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), which is being conducted virtually from November 13-15.

“Presenting all available treatment options to patients is an important part of HAE clinical management. These data continue to demonstrate the potential of berotralstat as a prophylactic medication, if approved by the FDA, with sustained reduction in attacks and meaningful improvements in quality of life seen over 48 weeks of treatment. With its oral, once-daily administration, berotralstat would offer patients a therapeutic alternative for managing this chronic disease,” said H. James Wedner, M.D., the Dr. Phillip and Arleen Korenblat Professor of Medicine at Washington University School of Medicine in St. Louis, and lead author of the Distinguished Industry Oral Abstract.

Following is a brief description of the clinical data posters being presented at ACAAI.


Berotralstat Reduces Attacks in Patients with Hereditary Angioedema (HAE): APeX-2 Trial 48 Week Results

; Distinguished Industry Oral Abstract, Session A, Friday, November 13, 4:30-5:30 p.m. CT

Patients treated with oral, once-daily berotralstat 150 mg for 48 weeks experienced a sustained reduction in mean investigator confirmed HAE attack rates through month 12.

In patients re-randomized to berotralstat 150 mg after 24 weeks on placebo, there was a marked reduction in investigator-confirmed HAE attack rates over 24 weeks of treatment. These patients had a mean attack rate per month of 2.5 at baseline, 1.7 at month six (while on placebo), 0.6 at month seven (one month after starting berotralstat 150 mg) and 0.6 at month 12 (six months after starting berotralstat 150 mg).  

Berotralstat was generally well-tolerated in APeX-2 through 48 weeks. The safety profile observed from weeks 24 to 48 was consistent with the data observed through the first 24 weeks. The most commonly reported treatment-related adverse events were upper respiratory tract infection, abdominal pain, diarrhea and vomiting.


Berotralstat Positively Impacts Patient-Reported Satisfaction: Results from the Phase 3 APeX-2 trial

; Poster #158

Patient satisfaction with treatment was assessed using the validated Treatment Satisfaction Questionnaire for Medicine (TSQM), which is comprised of three specific scales (side effects, effectiveness and convenience) and is scored on a global satisfaction scale from 0-100.

HAE patients who transitioned from placebo to berotralstat 150 mg at week 24 reported improved overall treatment satisfaction and effectiveness. These patients experienced statistically significant improvements from weeks 24 to 48, with a mean global satisfaction increase of 26 points (p=0.005) and a mean effectiveness increase of 29.6 points (p<0.001).   Convenience scores remained high through week 48, reflecting the positive experiences patients had taking an oral medication.


Berotralstat Improves Patient-Reported Quality of Life Through 48 Weeks in the Phase 3 APeX-2 Trial
; Poster #154

Quality of life was assessed with the Angioedema Quality-of-Life (AE-QoL) questionnaire, a validated tool to measure impairment of QoL based on a total and domain (functioning, fatigue/mood, fear/shame and nutrition) scores. The minimal clinically important difference (MCID) is defined as an improvement of six points.

Clinically meaningful improvements in mean AE-QoL total scores were observed as early as week four, with a mean improvement from baseline of 15 points at week 24. This improvement was sustained through 48 weeks of treatment with berotralstat 150 mg.

Improvements were observed in all four domains (functioning, fatigue/mood, fear/shame, nutrition) through week 48. Notably, 77 percent of patients exceeded the MCID in total AE-QoL total scores at 48 weeks, indicating the reduction in attacks following berotralstat therapy appears to have a positive impact on patients’ quality of life.

About
the
APeX-2
Trial
In APeX-2, 121 eligible HAE type 1 or type 2 patients were randomized 1:1:1 to oral, once daily berotralstat 110 mg or 150 mg or placebo for 24 weeks. At 24 weeks, patients initially randomized to 110 mg or 150 mg of berotralstat continued on that dose. Patients who initially received placebo were re-randomized 1:1 at week 24 to receive either berotralstat 110 mg or 150 mg.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including ORLADEYO (berotralstat), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company’s website at www.BioCryst.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; developing and commercializing ORLADEYO or any HAE product candidate may take longer or may be more expensive than planned; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, may impose a clinical hold with respect to such product candidates, or may withhold market approval for product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its product candidates, manage its growth, and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that 2020 operating expenses and cash usage may not be within management’s expected ranges.  Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s forward-looking statements.

BCRXW


Contact:


John Bluth
+1 919 859 7910
[email protected]

Catherine Collier Kyroulis
+1 917 886 5586
[email protected]

ReneSola Power to Release Third Quarter 2020 Financial Results on December 1, 2020

PR Newswire

STAMFORD, Conn., Nov. 13, 2020 /PRNewswire/ — ReneSola Ltd (“ReneSola Power” or the “Company”) (www.renesolapower.com) (NYSE: SOL), a leading fully integrated solar project developer, announced today that it will report its unaudited financial results for the third quarter ended September 30, 2020 after the U.S. stock market close on Tuesday, December 1, 2020. The Company will hold a conference call to discuss the financial results at 4:30 p.m. U.S. Eastern Time on Tuesday, December 1, 2020 (5:30 a.m. China Standard Time on Wednesday, December 2, 2020).

What:              ReneSola Ltd Third Quarter (ended September 30, 2020) Earnings Call
When:             4:30 p.m. U.S. Eastern Time on Tuesday, December 1, 2020 (5:30 a.m. China Standard Time on Wednesday, December 2, 2020)
Webcast:        http://ir.renesolapower.com/webcasts-presentations

Please register in advance to join the conference call using the link provided below and dial in 10 minutes before the call is scheduled to begin. Conference call access information will be provided upon registration.

Participant Online Registration: http://apac.directeventreg.com/registration/event/7488976

A replay of the conference call may be accessed by phone at the following numbers until December 9, 2020. To access the replay, please reference the conference ID 7488976.


Phone Number


Toll-Free Number

United States

+1 (646) 254-3697

+1 (855) 452-5696

Hong Kong

+852 3051-2780

+852 8009-63117

Mainland China

+86 (800) 870-0206

+86 (400) 602-2065

Other International

+61 (2) 8199-0299

A webcast of the conference call will be available on the ReneSola Power website at http://ir.renesolapower.com.

About ReneSola Power

ReneSola Power (NYSE: SOL) is a leading global solar project developer and operator. The Company focuses on solar power project development, construction management and project financing services. With local professional teams in more than 10 countries around the world, the business is spread across a number of regions where the solar power project markets are growing rapidly, and can sustain that growth due to improved clarity around government policies. The Company’s strategy is to pursue high-margin project development opportunities in these profitable and growing markets; specifically, in the U.S. and Europe, where the Company has a market-leading position in several geographies, including Poland, Hungary, Minnesota and New York.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/renesola-power-to-release-third-quarter-2020-financial-results-on-december-1-2020-301172511.html

SOURCE ReneSola Ltd.

Village Farms International Reports Third Quarter 2020 Financial Results – Pure Sunfarms Delivers Seventh Consecutive Profitable Quarter, Nearly Tripling Net Income Sequentially on a 75% Sequential Net Sales Increase as Produce Business Continues Strong Performance

PR Newswire


– Pure Sunfarms Brand Achieves 15.2% Dried Flower Market Share (by Volume) with OSC in October –

VANCOUVER, BC, Nov. 13, 2020 /PRNewswire/ – Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) (TSX: VFF) today announced its financial results for the three and nine months ended September 30, 2020.  All figures are in U.S. dollars unless otherwise indicated. 

The Company’s financial statements for the three and nine months ended September 30, 2020, as well as the comparative periods for 2019, have been prepared and presented under United States Generally Accepted Accounting Principals (“GAAP”). On September 30, 2020, Village Farms had a majority (non-controlling) interest of 58.7% of Pure Sunfarms Corp. (“Pure Sunfarms”), as the full acquisition of the remaining interest in Pure Sunfarms did not occur till November 2, 2020. Accordingly, Pure Sunfarms results are not consolidated for the third quarter.

Pure Sunfarms’ Third Quarter and Other Recent Highlights

(Dollar Amounts are Before Village Farms’ Proportionate Share)

  • Achieved significant sequential quarterly growth in key financial metrics for the third quarter of 2020 compared to the second quarter of 2020:
    • Net sales increased 75% to C$22.6 million;
    • Net sales to provincial buyers (retail) increased 30% to C$12.0 million;
    • Gross profit increased 81% to C$7.8 million;
    • Net income increased 200% to C$3.2 million; and
    • Adjusted EBITDA increased 125% to C$5.6 million.
  • Achieved 15.2% brand market share of the dried flower category (by kilograms sold) in October 2020 with the Ontario Cannabis Store (“OCS”)*;
  • Remained the top-selling brand of dried flower products with the OCS (by kilograms sold and dollars sold) for the year-to-date ended October 31, 2020, with a market share of 13.6% (by kilograms sold)*;
  • Launched its first Cannabis 2.0 products, specifically Full Spectrum Vapes in 510 Thread Cartridges and first bottled oil products, in September 2020; and,
  • Received an amendment to its standard cannabis processing license from Health Canada permitting internal extraction operations, which are currently ramping up.

*Data cited has been calculated by Pure Sunfarms from sales information provided by OCS.

Village Farms’ Financial Summary for the Three and Nine Months Ended September 30, 2020 and Corporate Highlights

($US millions except per share metric)


Three Months Ended   
September 30,


Nine Months Ended      
September 30,


2020


2019


Change


2020


2019


Change

Produce Sales

$43.0

$38.3

+12%

$122.7

$111.5

+10%

Net Income (Loss)1

$0.5

($0.7)

+171%

$4.63

$9.52

-52%

Income (Loss) Per Share1

$0.01

($0.01)

+200%

$0.083

$0.202

-60%

Adjusted EBITDA4

$4.6

$2.9

+59%

$7.9

$8.3

-5%

1.

Net income includes the net income contribution from Pure Sunfarms of US$1.4 million and US$3.7 million (Village Farms’ proportionate share) for the three-month periods ended September 30, 2020 and 2019, respectively and US$5.4 million and US$14.5 million (Village Farms’ proportionate share) for the nine-month periods ended September 30, 2020 and 2019, respectively.

2.

Net income for the nine months ended September 30, 2019 includes a one-time gain on the sale of Delta 2 greenhouse facility of $13.6 million.

3.

Net income for the nine months ended September 30, 2020 includes a $4.7 million gain on receipt of Pure Sunfarms shares from Emerald Health Therapeutics as per the Settlement Agreement and Mutual Release, dated March 2, 2020, by and between Village Farms International, Inc., Emerald Health Therapeutics Inc., Emerald Health Therapeutics Canada Inc., and Pure Sunfarms Corp. (the “Settlement Agreement”).

4.

Adjusted EBITDA includes the positive EBITDA contribution from Pure Sunfarms of US$2.5 million and US$5.0 million (Village Farms’ proportionate share) for the three-month periods ended September 30, 2020 and 2019, respectively and US$6.4 million and US$17.7 million (Village Farms’ proportionate share) for the nine-month periods ended September 30, 2020 and 2019, respectively.  Adjusted EBITDA includes the Company’s majority non-controlling interest in Pure Sunfarms and 65% equity interest in Village Fields Hemp USA LLC (“VF Hemp”), (together the “Joint Ventures” or “JVs”). Adjusted EBITDA is not a recognized earnings measure and does not have a standard meaning prescribed in by GAAP. See “Non-GAAP Measures” below.

 

  • On November 2, 2020 (subsequent to quarter end), the Company acquired all issued and outstanding shares of Pure Sunfarms, as a result of which the Company now wholly owns 100% of Pure Sunfarms;
  • In September 2020, the Company completed a registered direct offering of 9,396,226 units at a purchase price of US$5.30 per unit with certain institutional investors for gross proceeds of approximately $49.8 million, of which a portion of the proceeds were used to finance the Pure Sunfarms acquisition;
  • The Company initiated its international cannabis strategy with investments in Australia-based Altum International Pty Ltd, one of Asia-Pacific’s leading cannabinoid platforms, and DutchCanGrow, a Netherlands-based cannabis enterprise pursuing the opportunity to become one of a limited number of licensed cannabis growers when the Dutch government permits the first legal recreational cannabis market in Europe; and
  • Subsequent to quarter end, the Company’s wholly owned subsidiary, Village Farms Clean Energy, Inc. (“VFCE”), renewed and extended its existing contract with the City of Vancouver under which VFCE receives landfill gas captured by the City of Vancouver at the City’s landfill site in Delta, BC, enabling the transition of VFCE to a more attractive long-term business model based on the conversion of landfill gas to high-demand Renewable Natural Gas.

Pure Sunfarms’ Financial Summary for the Three and Nine Months Ended September 30, 2020
(Before Village Farms’ Proportionate Share)
   

(millions except % metrics)


Three Months Ended September 30,


2020


2019


Change of C$


C$


US$


C$


US$

Total Gross Sales

$28.8

$21.7

$24.8

$18.7

+16%

Total Net Sales

$22.6

$17.0

$24.0

$18.1

-6%

Gross Margin

34%

35%

69%

69%

-51%

SG&A

$3.3

$2.4

$3.7

$2.8

-11%

Net income

$3.2

$2.5

$8.9

$6.7

-64%

Adjusted EBITDA5

$5.6

$4.3

$13.4

$10.1

-58%

Adjusted EBITDA Margin

25%

25%

56%

56%

-55%

 

(millions except % metrics)


Nine Months Ended September 30,


2020


2019


Change of C$


C$


US$


C$


US$

Total Gross Sales

$69.6

$51.4

$71.5

$53.8

-2%

Total Net Sales

$53.5

$39.6

$70.7

$53.1

-24%

Gross Margin

40%

40%

75%

75%

-47%

SG&A

$9.1

$6.7

$7.5

$5.6

+21%

Net income6

$12.9

$9.4

$32.1

$24.1

-60%

Adjusted EBITDA5

$14.9

$11.0

$47.1

$35.4

-68%

Adjusted EBITDA Margin

28%

28%

67%

67%

-58%

5.

Adjusted EBITDA is not a recognized earnings measure and does not have a standard meaning prescribed in by GAAP. See “Non-GAAP Measures” below.

6.

Net income includes C$6.0 million of debt forgiveness income as an outcome of the Settlement Agreement.

 

Pure Sunfarms’ Percent of Sales by Product Group


Three months ended
September 30,


Nine months ended
September 30,


Channel


2020


2019


2020


2019

Retail, Flower

48.5%

11.1%

52.3%

3.8%

Retail, 2.0 Product

4.5%

0.0%

1.9%

0.0%

Wholesale, Flower and Trim

47.0%

88.9%

45.8%

96.2%

Management Commentary

“With 75% sequential growth in dollar sales, Pure Sunfarms’ third quarter highlighted its strong sales momentum as its leading brand continues to resonate with consumers,” said Michael DeGiglio, CEO, Village Farms.  “Importantly, this sales momentum was achieved with only a small contribution from Pure Sunfarms’ Cannabis 2.0 and bottled oil products, which were launched late in the quarter.  Pure Sunfarms’ third quarter results are yet further evidence of its earnings power, based on our unique approach to the cannabis industry, with net income nearly tripling from the second quarter of this year, marking Pure Sunfarms seventh consecutive quarter of profitability.  It is an achievement that is unmatched in our industry, and further underscores the significant value in acquiring the entirety of Canada’s premier cannabis company.”

Mr. DeGiglio added, “The deep experience and organizational strength underlying our legacy produce business, which delivered another solid quarter, combined with our proven cannabis capabilities provides Village Farms with a rock-solid foundation as we transform to a vertically integrated, agriculturally-based CPG business to aggressively pursue high-growth opportunities in emerging legal cannabis and related markets in the United States and other targeted markets.  There is no cannabis supplier in Canada or the U.S. with our combination of experience, capabilities and more than ten million square feet of greenhouse assets, and we are encouraged by the evolving regulatory environment in the U.S. and are developing multiple strategies to capitalize on any favourable U.S. regulatory developments in 2021.  We will pursue these opportunities with prudent, disciplined capital allocation and focus on return on invested capital.”

COVID-19 Update

All Village Farms’ production facilities in Texas, British Columbia, and Pure Sunfarms’ facilities in Canada remain open and operational. The Company has experienced a small number of COVID-19 illnesses at its facilities, however, the Company’s protocols were followed and there has been no material disruption to operations. Village Farms and Pure Sunfarms adhere to the highest health and safety standards in their operations and each has put in place heightened hygiene practices and safety protocols, including more stringent cleaning and sanitization, and are taking appropriate precautions throughout all operations as per the recommendations of health authorities.  The Company will continue to enhance and evolve such practices and protocols as the situation warrants.

Summary Statutory Results


(in thousands of U.S. Dollars unless otherwise indicated)


For the three months
ended September 30,


For the nine months
ended September 30,


2020


2019


2020


2019

Sales

$43,037

$38,293

$122,722

$111,512

Cost of sales

(37,418)

(38,904)

(112,809)

(114,418)

Selling, general and administrative expenses

(4,942)

(3,739)

(12,676)

(11,899)

Stock compensation expense

(472)

(666)

(1,329)

(2,663)

Interest expense

(299)

(655)

(1,273)

(2,018)

Interest income

101

304

577

651

Foreign exchange (loss) gain

(484)

(183)

(880)

338

Gain on settlement

4,681

Other income, net

27

69

92

219

(Loss) gain on disposal of assets

(8)

(6)

13,558

(Provision for) recovery of income taxes

(336)

1,266

607

114

Equity earning from unconsolidated entities

1,306

3,519

4,885

14,115

Net income (loss)

$520

($704)

$4,591

$9,509

 

Adjusted EBITDA7

$4,556

$2,881

$7,921

$8,326

Income (loss) per share – basic

$0.01

($0.01)

$0.08

$0.20

Income (loss) per share – diluted

$0.01

($0.01)

$0.08

$0.19

7.

Adjusted EBITDA is not a recognized earnings measure and does not have a standard meaning prescribed in by GAAP. See “Non-GAAP Measures” below.

 

Pure Sunfarms (in C$)


Three months ended September 30, 2020 compared to the three months ended June 30, 2020.

Sales

Sales for three months ended September 30, 2020 increased to $22,627 as compared to $12,902, or a 75% quarter on quarter increase from the three months ended June 30, 2020 sales .  The increase was primarily driven by a 148% increase in sales in the wholesale channel, a 30% quarter on quarter increase in sales to provincial (retail) boards and the September launch of Pure Sunfarms Cannabis 2.0 derivative products, which includes cannabis oil and vape pens. The quarter on quarter growth in retail sales is directly attributable to a 165.7% increase in Pure Sunfarms retail small format, a 29.7% quarter on quarter increase in pre-rolls and a (42.7%) decrease in Pure Sunfarms retail large format, as the large format was launched in the second quarter of 2020 and the third quarter retail large format sales consisted of ongoing replenishment sales.

The channel makeup of the third quarter sales was 53% to the retail channel and 47% to the wholesale channel.  The channel makeup of the second quarter sales was 69% to the retail channel and 31% to the wholesale channel.  Cannabis 2.0 derivative products were 4.5% of third quarter sales, which are included in the retail channel.

The net average selling price for the three months ended September 30, 2020 was higher than the net average selling price for the three months ended June 30, 2020 by 13.3% due to an increase in small format retail sales versus large format retail sales, a quarter on quarter increase in the sales price of retail flower SKUs and a slight increase in wholesale pricing, which is impacted by the makeup of the potency of flower biomass sold to various wholesale customers.

Cost of Sales

Cost of sales for the three months ended September 30, 2020 and three months ended June 30, 2020 was $14,826 and $8,594, respectively, an increase of 73%. The third quarter of 2020 cost of sales includes an inventory write down of ($1,412) for distillate inventory purchased from third party extraction companies for which the market value has dropped since the initial purchase. The quarter on quarter increase in costs excluding the distillate inventory write down was 56%, primarily due to a 143% increase in wholesale kilograms sold, a 120% increase in retail small format kilograms sold which has higher overhead and labor cost compared to retail large format, and the launch of recently approved Cannabis 2.0 products which was co-manufactured by another licensed producer.

Gross Margin

Gross margin for the three months ended September 30, 2020 and three months ended June 30, 2020 was 34.5% and 33.2%, respectively, excluding the distillate inventory write down the third quarter gross margin was 40.7%. The quarter on quarter improvement was due to an increase in wholesale sell price and an increase in small format retail flower sales as compared to higher sales of Pure Sunfarms retail large format products in the second quarter of 2020, which have a lower gross margin.

Net Income

Net income for the three months ended September 30, 2020 and three months ended June 30, 2020 was $3,240 and $1,079 respectively, an increase of 200%. The increase was primarily due to the increase in gross margin.

Adjusted EBITDA

Adjusted EBITDA for the three months ended September 30, 2020 increased 125% to $5,642 from $2,509 for the second quarter.  The third quarter Adjusted EBITDA figure includes the third-party distillate inventory write down of ($1,412).

Pure Sunfarms (in C$)


Three months ended September 30, 2020 compared to the three months ended September 30, 2019.

Sales

Sales for the three months ended September 30, 2020 and 2019 was $22,627 and $23,953, respectively, a decrease of (5.5%). The change was due to 362% increase in provincial (retail) sales and (51.6%) decrease in wholesale selling price for the three months ended September 30, 2020 compared to the three months ended September 30, 2019.  The net average selling price of retail flower for the three months ended September 30, 2020 was lower than the net average selling price for the three months ended September 30, 2019 by (35.8%).

Cost of Sales

Cost of sales for the three months ended September 30, 2020 and 2019 was $14,826 and $7,536, respectively, an increase of 97%. The third quarter 2020 cost of sales includes an inventory write down of ($1,412) for distillate inventory purchased from their third-party extraction companies for which the market value has dropped since the initial purchase. The year on year increase in costs excluding the distillate inventory write down was 78%, primarily due to a 553% increase in retail kilograms sold which require incremental packaging, overhead and logistics expenses compared to product sold through the wholesale channel, as well as higher depreciation expense charge (a year on year increase of 91%).

Gross Margin

Gross margin for the three months ended September 30, 2020 and 2019 was 34.5% and 68.5%, respectively. The decline was due to the ($1,412) inventory write down for distillate inventory in 2020, a lower price environment for the wholesale channel in 2020 as compared to the third quarter of 2019, as well as an increase in costs as a result of Pure Sunfarms’ increase in provincial (retail) sales in 2020, as the majority of sales in the third quarter of 2019 were made through the wholesale channel.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended September 30, 2020 and 2019 were $3,261 and $3,741, respectively, a decrease of 12.8%. The decrease was primarily due to wage subsidies received from the Government of Canada as a result of the federal COVID-19 program. Without the subsidy, the year on year selling, general and administrative expenses were essentially flat. 

Net Income

Net income for the three months ended September 30, 2020 and 2019 was $3,240 and $8,860 respectively, a decrease of (63.4%). The decrease was primarily due to the decrease in gross margin.

Adjusted EBITDA

Adjusted EBITDA for the three months ended September 30, 2020 declined (57.7%) to $5,642 from $13,352 for the same prior year period. The decrease was primarily due to the decrease in gross margin.

Produce (in US$)


Three months ended September 30, 2020 compared to the three months ended September 30, 2019

.

Sales

Produce sales for the three months ended September 30, 2020 increased $4,744, or 12.4%, to $43,037 compared to $38,293 for the three months ended September 30, 2019. The improvement in sales is due to an increase in pricing for tomatoes during the three months ended September 30, 2020 compared to the same prior year period. The average net selling price for total tomato pounds sold increased 30% for the three months ended September 30, 2020 compared to the three months ended September 30, 2019, generated primarily from our commodity items, which includes beefsteak tomatoes and tomatoes on the vine (“TOVs”). The increase in net selling price in the commodity items was primarily the result of a supply shortage throughout most of 2020, due to an increase in grocery store traffic, driven by COVID-19 measures, as well as a global tomato virus that is negatively impacting tomato supplies. Pepper prices increased 19% and pepper pounds sold increased 47% when compared to the same prior year period, due to an increase in our third-party pepper contracts. Cucumber prices increased 1% and cucumber pieces sold decreased (12%) for the three months ended September 30, 2020 as compared to the three months ended September 30, 2019.

Cost of Sales

Cost of sales for the three months ended September 30, 2020 decreased ($1,486), or (3.8%), to $37,418 from $38,904 for the three months ended September 30, 2019, as the Company produced less tomatoes at its facilities in the third quarter of 2020 compared to the same period in 2019 due to the transition of the Delta 2 facility, which converted from tomato production in 2019 to cannabis production for Pure Sunfarms in 2020.

Adjusted EBITDA

Adjusted EBITDA for the three months ended September 30, 2020 increased $4,168 to $2,223 from ($1,945) for the three months ended September 30, 2019 due primarily to an increase in gross margin, partially offset by an increase in selling, general and administrative expenses. See the reconciliation of Adjusted EBITDA to net income in “Non-GAAP Measures” below.

Non-GAAP Measures

References in this news release to “Adjusted EBITDA” are to earnings (including the equity in earnings of the Joint Ventures) before interest, taxes, depreciation and amortization (“EBITDA”), as further adjusted to exclude foreign currency exchange gains and losses on translation of long-term debt, unrealized gains on the changes in the value of derivative instruments, stock compensation, and gains and losses on asset sales, and adjusts for the difference in accounting treatment of Pure Sunfarms, which we believe is necessary to reflect the true economic value of our interest in Pure Sunfarms.  Adjusted EBITDA is a cash flow measure that is not recognized under GAAP and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA may not be comparable to similar measures presented by other issuers. Although net income or loss is the most directly comparable financial measure calculated and presented in accordance with GAAP, investors are cautioned that Adjusted EBITDA should not be construed as an alternative to net income or loss determined in accordance with GAAP as an indicator of the Company’s performance or to cash flows from operating, investing and financing activities as measures of liquidity and cash flows. Management believes that Adjusted EBITDA is an important measure in evaluating the historical performance of the Company. 

We also present Adjusted EBITDA, earnings per share and diluted earnings per share on a proportionate segment basis. Each of the components of Adjusted EBITDA, on a proportionate segment basis, are presented in the tables below that present a reconciliation of GAAP results to proportionate results. We believe that the ability of investors to assess our overall performance may be improved by the disclosure of proportionate segment Adjusted EBITDA, earnings per share and diluted earnings per share.

The following table reflects a reconciliation of net income to Adjusted EBITDA, as presented by the Company:


(in thousands of U.S. dollars)


For the three months
ended September 30,


For the nine months
ended September 30,


2020


2019


2020


2019

Net income (loss)

$520

($704)

$4,591

$9,509

Add:

Amortization

1,518

2,360

4,540

5,587

Foreign currency exchange loss (gain)

484

183

880

(338)

Interest expense, net

198

351

696

1,367

Provision for (recovery of) income taxes

336

(1,266)

(607)

(114)

Stock based compensation

472

666

1,329

2,663

Interest expense for JVs

240

276

636

506

Amortization for JVs

598

414

1,276

1,125

Foreign currency exchange loss (gain) for JVs

33

(8)

118

(21)

Income taxes provision from JVs

245

1,355

1,736

5,572

(Gain) loss on disposal of assets

(88)

8

(97)

(13,558)

Gain on settlement agreement

(4,681)

JV gain on settlement of net liabilities

(2,496)

True economic benefit Pure Sunfarms8

(754)

(3,972)

Adjusted EBITDA

$4,556

$2,881

$7,921

$8,326

Adjusted EBITDA for JVs (See table below)

$2,333

$4,826

$6,050

$17,346

Adjusted EBITDA excluding JVs(produce)

$2,223

($1,945)

$1,871

($9,020)

8.

The GAAP treatment of our equity earning of Pure Sunfarms is different than under International Financial Reporting Standards (“IFRS”). Under GAAP the Emerald shares held in escrow are not considered issued until paid for pursuant to the GAAP concept of ‘hypothetical liquidation’. As a result, our ownership percentage for the three and nine months ended September 30, 2019 was 61.4% and 60.8%, respectively, compared to our economic interest under IFRS of 50% for the same periods.

 


Breakout of JV’s Adjusted EBITDA


(in thousands of U.S. dollars)


For the three months
ended September 30,


For the nine months
ended September 30,


2020


2019


2020


2019

Pure Sunfarms Adjusted EBITDA

$2,551

$5,035

$6,365

$17,710

VFH Adjusted EBITDA

(178)

(209)

(315)

(364)

Total JV’s Adjusted EBITDA

$2,333

$4,826

$6,050

$17,346

 

The following tables are a reconciliation of the GAAP results to the proportionate results (which include the Company’s proportionate share of the Pure Sunfarms operations):


For the three months ended September 30, 2020


(in thousands of U.S. dollars)

 

Produce

Pure
Sunfarms9

 

Hemp9

 

Total

Sales

$43,037

$10,007

$-

$53,044

Cost of sales

(37,418)

(6,547)

(43,965)

Gross margin

5,619

3,460

9,079

Selling, general and administrative expenses

(4,942)

(1,436)

(213)

(6,591)

Share-based compensation

(472)

(472)

Interest expense

(299)

(227)

(14)

(540)

Interest income

101

101

Foreign exchange loss

(484)

(33)

(517)

Other income (expense)

27

(76)

1

(48)

Gain on disposal of assets

89

89

(Loss) income before taxes

(450)

1,688

(137)

(1,101)

Recovery of (provision for) income taxes

(336)

(245)

(581)

Net (loss) income

($786)

$1,443

($137)

$520

Adjusted EBITDA10

$2,223

$2,511

($178)

$4,556

(Loss) income per share – basic

($0.01)

$0.02

($0.00)

$0.01

(Loss) income per share – diluted

($0.01)

$0.02

($0.00)

$0.01


For the three months ended September 30, 2019

 (in thousands of U.S. dollars)

 

Produce

Pure
Sunfarms9

 

Hemp9

 

Total

Sales

$38,293

$10,217

$-

$48,510

Cost of sales

(38,904)

(3,211)

(42,115)

Gross margin

(611)

7,006

6,395

Selling, general and administrative expenses

(3,739)

(1,635)

(229)

(5,603)

Share-based compensation

(666)

(666)

Interest expense

(655)

(175)

(830)

Interest income

304

304

Foreign exchange (loss) gain

(183)

8

(175)

Other income

69

5

74

Loss on disposal of assets

(8)

(8)

(Loss) income before taxes

(5,489)

5,209

(229)

(509)

Recovery of (provision for) income taxes

1,266

(1,461)

(195)

Net (loss) income

($4,223)

$3,748

($229)

($704)

Adjusted EBITDA10

($1,945)

$5,035

($209)

$2,881

(Loss) income per share – basic

($0.09)

$0.08

($0.00)

($0.01)

(Loss) income per share – diluted

($0.09)

$0.08

($0.00)

($0.01)


For the nine months ended September 30, 2020


(in thousands of U.S. dollars)

 

Produce

Pure
Sunfarms9

 

Hemp9

 

Total

Sales

$122,722

$22,958

$98

$145,778

Cost of sales

(112,809)

(13,782)

(120)

(126,711)

Gross margin

9,913

9,176

(22)

19,067

Selling, general and administrative expenses

(12,676)

(3,870)

(500)

(17,046)

Share-based compensation

(1,329)

(1,329)

Interest expense

(1,273)

(425)

(211)

(1,909)

Interest income

577

577

Foreign exchange loss

(880)

(117)

(997)

Gain on settlement

4,681

4,681

JV gain on settlement

2,496

2,496

Other income (expense)

92

(92)

82

82

(Loss) gain on disposal of assets

(6)

5

99

98

(Loss) income before taxes

(901)

7,173

(552)

5,720

Recovery of (provision for) income taxes

607

(1,736)

(1,129)

Net (loss) income

($294)

5,437

(552)

4,591

Adjusted EBITDA10

$1,871

6,365

(315)

7,921

(Loss) income per share – basic

($0.01)

$0.10

($0.01)

$0.08

(Loss) income per share – diluted

($0.01)

$0.10

($0.01)

$0.08


For the nine months ended September 30, 2019

 (in thousands of U.S. dollars)

 

Produce

Pure
Sunfarms9

 

Hemp9

 

Total

Sales

$111,512

$32,011

$-

$143,523

Cost of sales

(114,418)

(8,137)

(122,555)

Gross margin

(2,906)

23,874

20,968

Selling, general and administrative expenses

(11,899)

(3,334)

(378)

(15,611)

Share-based compensation

(2,663)

(2,663)

Interest expense

(2,018)

(356)

(2,374)

Interest income

651

651

Foreign exchange gain

338

22

360

Other income

219

12

231

Gain on disposal of assets

13,558

13,558

(Loss) income before taxes

(4,720)

20,218

(378)

15,120

Recovery of (provision for) income taxes

114

(5,725)

(5,611)

Net (loss) income

($4,606)

$14,493

($378)

$9,509

Adjusted EBITDA10

($9,020)

$17,710

($364)

$8,326

(Loss) income per share – basic

($0.09)

$0.30

($0.01)

$0.20

(Loss) income per share – diluted

($0.09)

$0.29

($0.01)

$0.19

9.

The adjusted consolidated financial results have been adjusted to include the Company’s share of revenues and expenses from its Pure Sunfarms and Hemp joint ventures on a proportionate accounting basis, on which management bases its operating decisions and performance evaluation.  GAAP does not allow for the inclusion of the Joint Venture on a proportionate basis.  These results include additional non-GAAP measures such as EBITDA.

10.

Adjusted EBITDA is not a recognized earnings measure and does not have a standard meaning prescribed in by GAAP. See “Non-GAAP Measures” above.

 

Pro Forma Results

The combined pro forma financial information being presented is for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the transaction occurred as of January 1, 2020, nor do they purport to project the future operating results of the consolidated company. The pro forma financial information also does not reflect the costs of any integration activities or cost savings or synergies expected to be achieved as a result of the transaction and, accordingly, do not attempt to predict or suggest future results.

The combined pro forma financial information being presented is based on preliminary estimates, accounting judgments and currently available information and assumptions that management believes are reasonable. Accordingly, this pro forma financial data is not necessarily indicative of our financial position or results of operations had the Pure Sunfarms acquisition described above for which we are giving pro forma effect actually occurred on the date indicated.

The following tables present pro forma GAAP results as if the Company’s owned 100% of the Pure Sunfarms operations as of January 1, 2020:


For the three months ended September 30, 2020

 


(in thousands of U.S. dollars)

Historical

Village Farms

Historical
Pure Sunfarms

Pro Forma
Adjustments

Pro Forma
Combined

Consolidated sales

$43,037

$17,048

$-

$60,085

Cost of sales

(37,418)

(11,154)

(48,572)

Gross margin

5,619

5,894

11,513

Selling, general and administrative expenses

 

(4,942)

 

(2,447)

 

 

(7,389)

Share-based compensation

(472)

(472)

Interest expense

(299)

(386)

100

(585)

Interest income

101

(100)

1

Foreign exchange loss

(484)

(56)

(540)

Other income (expense)

27

(131)

(104)

(Loss) income before taxes

(450)

2,874

2,424

(Provision for) recovery of income taxes

 

(336)

 

(417)

 

 

(753)

(Loss) gain from consolidated entities after income taxes

 

(786)

 

2,457

 

 

1,671

Equity earnings of unconsolidated entities

 

1,306

 

 

(1,443)

 

(137)

Net income (loss)

$520

$2,457

($1,443)

$1,534

Income per share – basic

$0.01

$0.02

Income per share – diluted

$0.01

$0.02

Weighted average number of common shares – basic

 

58,536

7,354

 

65,890

Weighted average number of common shares – diluted

 

60,440

7,808

 

68,248

Adjusted EBITDA

$4,556

$4,277

($2,511)

$6,322


For the nine months ended September 30, 2020

 


(in thousands of U.S. dollars)

Historical

Village Farms

Historical
Pure Sunfarms

Pro Forma
Adjustments

Pro Forma
Combined

Consolidated sales

$122,722

$39,571

$-

$162,293

Cost of sales

(112,809)

(23,678)

(136,487)

Gross margin

9,913

15,893

25,806

Selling, general and administrative expenses

(12,676)

(6,731)

(19,407)

Share-based compensation

(1,329)

(1,329)

Interest expense

(1,273)

(734)

309

(1,698)

Interest income

577

(309)

268

Foreign exchange loss

(880)

(207)

(1,087)

Gain on settlement

4,681

4,348

9,029

Other income (expense)

92

(146)

(54)

Loss on disposal of assets

(6)

(6)

(Loss) income before taxes

(901)

12,423

11,522

Recovery of (provision for) income taxes

 

607

 

(3,012)

 

(2,405)

Loss from consolidated entities after income taxes

 

(294)

 

9,411

9,117

Equity earnings of unconsolidated entities

 

4,885

 

 

(5,438)

(553)

Net income (loss)

$4,591

$9,411

($5,438)

$8,564

Income per share – basic

$0.08

$0.13

Income per share – diluted

$0.08

$0.13

Weighted average number of common shares – basic

 

55,946

 

8,676

 

64,622

Weighted average number of common shares – diluted

 

57,778

 

9,130

 

66,908

Adjusted EBITDA

$7,921

$10,980

($6,365)

$12,536

 

Within 75 days of November 2, 2020 (the closing date of the Pure Sunfarms acquisition), the Company will file with the U.S. Securities and Exchange Commission, on Form 8-K/A, historical financial statements for Pure Sunfarms, together with unaudited pro forma combined financial statements of the Company as if the Pure Sunfarms Transaction had occurred on January 1, 2020.

This press release is intended to be read in conjunction with the Company’s Consolidated Financial Statements (“Financial Statements”) and Management’s Discussion & Analysis (“MD&A”) for the three and nine month periods ended September 30, 2020 in the Company Form 10-Q, which will be filed on (www.sec.gov/edgar.shtml) and SEDAR (www.sedar.com) and will be available at www.villagefarms.com.

Conference Call

Village Farms’ management team will host a conference call, Friday, November 13, 2020, at 8:30 a.m. ET to discuss its financial results.  Participants can access the conference call by telephone by dialing (647) 427-7450 or (888) 231-8191, or via the Internet at: https://bit.ly/2HoYneE.

For those unable to participate in the conference call at the scheduled time, it will be archived for replay both by telephone and via the Internet beginning approximately one hour following completion of the call. To access the archived conference call by telephone, dial (416) 849-0833 or (855) 859-2056 and enter the passcode 9199257 followed by the pound key. The telephone replay will be available until Friday, November 20, 2020 at midnight (ET).  The conference call will also be archived on Village Farms’ website at http://villagefarms.com/investor-relations/investor-calls.

About Village Farms International, Inc.

Village Farms is one of the largest and longest-operating greenhouse growers in North America, and is leveraging its decades of experience in large-scale, low-cost intensive agriculture and as a vertically integrated produce supplier to pursue high-value, high-growth plant-based Consumer Packaged Goods opportunities in cannabis and CBD in North America and selected markets internationally.

In Canada, British-Columbia-based Pure Sunfarms is one of the single largest cannabis operations in the world, the lowest-cost greenhouse producer, one of the best-selling brands, and has generated profitability for seven consecutive quarters.

In the U.S., subject to compliance with all applicable U.S. federal and state laws, Village Farms is pursuing a strategy to become a leading developer and supplier of branded and white-labeled CBD products targeting “big box” and other major retailers and consumer packaged goods companies, and with one the largest greenhouse operations in country, is well positioned for the potential federal legalization of high-THC cannabis.

Internationally, Village Farms is strategically targeting selected, nascent, legal cannabis and CBD opportunities with significant long-term potential, with an initial focus on the Asia-Pacific region through its investment in Australia-based Altum International.


Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is subject to the safe harbor created by those sections. This press release also contains “forward-looking information” within the meaning of applicable Canadian securities law. We refer to such forward-looking statements and forward-looking information collectively as “forward-looking statements”. Forward-looking statements may relate to the Company’s future outlook or financial position and anticipated events or results and may include statements regarding the financial position, business strategy, budgets, expansion plans, litigation, projected production, projected costs, capital expenditures, financial results, taxes, plans and objectives of or involving the Company. Particularly, statements regarding future results, performance, achievements, prospects or opportunities for the Company, the greenhouse vegetable industry or the cannabis industry are forward-looking statements. In some cases, forward-looking information can be identified by such terms as “outlook”, “may”, “might”, “will”, “could”, “should”, “would”, “occur”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “try”, “estimate”, “predict”, “potential”, “continue”, “likely”, “schedule”, “objectives”, or the negative or grammatical variation thereof or other similar expressions concerning matters that are not historical facts. The forward-looking statements in this press release are subject to risks that may include, but are not limited to: our limited operating history, including that of Pure Sunfarms and our start-up operations of growing hemp in the United States; the legal status of Pure Sunfarms cannabis business; risks relating to obtaining additional financing, including our dependence upon credit facilities; potential difficulties in achieving and/or maintaining profitability; variability of product pricing; risks inherent in the cannabis, hemp and agricultural businesses; the ability of Pure Sunfarms to cultivate and distribute cannabis in Canada; existing and new governmental regulations, including risks related to regulatory compliance and licenses (e.g., Pure Sunfarms’ ability to obtain licenses for its Delta 2 greenhouse facility as well as additional licenses under the Canadian act respecting cannabis to amend to the Controlled Drugs and Substances Act, the Criminal Code and other Acts, S.C. 2018, c. 16 (Canada) for its Delta 3 greenhouse facility), and changes in our regulatory requirements; risks relating to conversion of our greenhouses to cannabis production for Pure Sunfarms; risks related to rules and regulations at the U.S. federal (Food and Drug Administration and United States Department of Agriculture), state and municipal levels with respect to produce and hemp; retail consolidation, technological advances and other forms of competition; transportation disruptions; product liability and other potential litigation; retention of key executives; labor issues; uninsured and underinsured losses; vulnerability to rising energy costs; environmental, health and safety risks, foreign exchange exposure, risks associated with cross-border trade; difficulties in managing our growth; restrictive covenants under our credit facilities; natural catastrophes; the ongoing and developing COVID-19 pandemic; and tax risks.

The Company has based these forward-looking statements on factors and assumptions about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Although the forward-looking statements contained in this press release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, that may cause the Company’s or the industry’s actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, the factors contained in the Company’s filings with securities regulators, including this press release. In particular, we caution you that our forward-looking statements are subject to the ongoing and developing circumstances related to the COVID-19 pandemic, which may have a material adverse effect on our business, operations and future financial results.

When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.


Village Farms International, Inc.


Condensed Consolidated Interim Statements of Financial Position


(In thousands of United States dollars, except share data)


(Unaudited)

September 30, 2020

December 31, 2019


ASSETS


Current assets

Cash and cash equivalents

$

54,666

$

11,989

Trade receivables

10,498

8,997

Inventories

15,301

15,918

Amounts due from joint ventures

10,954

15,418

Other receivables

637

342

Income tax receivable

440

713

Prepaid expenses and deposits

934

1,259

Total current assets

93,430

54,636


Non-current assets

Property, plant and equipment

59,663

63,158

Investment in joint ventures

63,164

41,334

Investment in in minority interests

1,226

Notes receivable – joint ventures

10,713

10,865

Deferred tax asset

9,693

7,999

Right-of-use assets

4,111

3,582

Other assets

1,827

1,834

Total assets

$

243,827

$

183,408


LIABILITIES


Current liabilities

Line of credit

$

3,000

$

2,000

Trade payables

9,667

12,653

Current maturities of long-term debt

2,294

3,423

Accrued liabilities

6,676

3,017

Operating lease liabilities – current

1,711

875

Finance lease liabilities – current

34

61

Total current liabilities

23,382

22,029


Non-current liabilities

Long-term debt

27,793

28,966

Deferred tax liability

2,211

1,873

Operating lease liabilities – non-current

2,465

2,690

Finance lease liabilities – non-current

12

34

Other liabilities

1,437

1,357

Total liabilities

57,300

56,949

Commitments and contingencies (note 15)


SHAREHOLDERS’ EQUITY

Common stock, no par value per share –
unlimited shares authorized; 65,959,810
shares issued and outstanding at September
30, 2020 and 52,656,669 shares issued and
outstanding at December 31, 2019

141,310

98,333

Additional paid in capital

16,892

4,351

Accumulated other comprehensive loss

(516)

(475)

Retained earnings

28,841

24,250

Total shareholders’ equity

186,527

126,459

Total liabilities and shareholders’ equity

$

243,827

$

183,408

 


Village Farms International, Inc.


Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss)


(In thousands of United States dollars, except per share data, unless otherwise noted)


(Unaudited)

Three Months Ended September 30, 

Nine Months Ended September 30, 

2020

2019

2020

2019

Sales

$

43,037

$

38,293

$

122,722

$

111,512

Cost of sales

(37,418)

(38,904)

(112,809)

(114,418)

Gross margin

5,619

(611)

9,913

(2,906)

Selling, general and administrative expenses

(4,942)

(3,739)

(12,676)

(11,899)

Share-based compensation

(472)

(666)

(1,329)

(2,663)

Interest expense

(299)

(655)

(1,273)

(2,018)

Interest income

101

304

577

651

Foreign exchange gain (loss)

(484)

(183)

(880)

338

Gain on settlement agreement

4,681

Other income

27

69

92

219

(Loss) gain on disposal of assets

(8)

(6)

13,558

Loss before taxes and earnings from unconsolidated
   entities

(450)

(5,489)

(901)

(4,720)

(Provision for) recovery of income taxes

(336)

1,266

607

114

Loss from consolidated entities after income taxes

(786)

(4,223)

(294)

(4,606)

Equity earnings from unconsolidated entities

1,306

3,519

4,885

14,115

Net income (loss)

$

520

$

(704)

$

4,591

$

9,509

Basic income (loss) per share

$

0.01

$

(0.01)

$

0.08

$

0.20

Diluted income (loss) per share

$

0.01

$

(0.01)

$

0.08

$

0.19

Weighted average number of common shares used in
the computation of net income (loss) per share (in
thousands):

Basic

58,536

48,845

55,946

48,650

Diluted

60,440

48,845

57,778

50,451

Net income (loss)

$

520

$

(704)

$

4,591

$

9,509

Other comprehensive income (loss):

Foreign currency translation adjustment

31

(22)

(41)

58

Comprehensive income (loss)

$

551

$

(726)

$

4,550

$

9,567

 


Village Farms International, Inc.


Condensed Consolidated Interim Statements of Cash Flows


(In thousands of United States dollars)


(Unaudited)

Nine Months Ended
September 30,

2020

2019


Cash flows provided by (used in) operating activities:

Net income

$

4,591

$

9,509

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

4,540

5,587

Amortization of deferred charges

57

57

Share of income from joint ventures

(4,885)

(14,115)

Interest expense

1,273

2,018

Interest income

(577)

(651)

Interest paid on long-term debt

(1,318)

(2,013)

Gain on settlement agreement

(4,681)

Loss (gain) on disposal of assets

6

(13,558)

Non-cash lease expense

(935)

(778)

Interest paid on finance leases

(3)

(6)

Share-based compensation

1,329

2,663

Deferred income taxes

(321)

(749)

Changes in non-cash working capital items

4,938

4,149

Net cash provided by (used in) operating activities

4,014

(7,887)


Cash flows used in investing activities:

Purchases of property, plant and equipment, net of rebate

(1,076)

(1,630)

Advances to joint ventures

(133)

(9,499)

Proceeds from sale of asset

52

Investment in joint ventures

(11,713)

(13)

Investment in minority interests

(1,226)

Net cash used in investing activities

(14,148)

(11,090)


Cash flows from financing activities:

Proceeds from borrowings

3,000

3,000

Repayments on borrowings

(4,326)

(3,591)

Proceeds from issuance of common stock

46,388

13,868

Issuance costs

(3,819)

Proceeds from exercise of stock options

251

109

Payments on capital lease obligations

(51)

(69)

Proceeds from exercise of warrants

11,369

466

Net cash provided by financing activities

52,812

13,783

Effect of exchange rate changes on cash and cash equivalents

(1)


Net increase (decrease) in cash and cash equivalents

42,677

(5,194)


Cash and cash equivalents, beginning of period

11,989

11,920


Cash and cash equivalents, end of period

$

54,666

$

6,726

 

Cision View original content:http://www.prnewswire.com/news-releases/village-farms-international-reports-third-quarter-2020-financial-results—pure-sunfarms-delivers-seventh-consecutive-profitable-quarter-nearly-tripling-net-income-sequentially-on-a-75-sequential-net-sales-increase-as-produce-bu-301172627.html

SOURCE Village Farms International, Inc.

Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update

PR Newswire

MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical and corporate update.

“We remain on track to reopen enrollment in the pivotal Phase 3 RAPID trial by year-end, and are confident that the updated study design will help us to best characterize the potential clinical utility of our product candidate etripamil in patients with paroxysmal supraventricular tachycardia (PSVT),” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “In light of the safety and efficacy data from the completed NODE-301 trial, as well as positive feedback from the physicians charged with treating patients with PSVT, we believe that etripamil has the potential to serve as a much needed at-home intervention for this population. Backed by a strong balance sheet, which includes gross proceeds of $51.7 million from our recent public offering, we look forward to continuing to execute the etripamil PSVT program, with the goal of bringing this investigational therapy to as many appropriate patients as possible if approved by the FDA.”

Recent Updates

  • Pivotal Phase 3 RAPID Trial on Track to Reopen by Year-End. The Company remains on track to reopen enrollment in the pivotal Phase 3 RAPID trial by the end of the year. The RAPID trial is expected to randomize up to 500 patients and will be completed after a total of 180 confirmed supraventricular tachycardia (SVT) events are reached. Patients in the RAPID trial will be randomized 1:1 to etripamil or placebo. To help maximize the potential treatment effect of etripamil, patients who do not experience symptom relief within 10 minutes of the first study drug administration will be directed to administer a second dose of study drug. As previously announced, the primary efficacy endpoint for both the RAPID trial and the already-completed NODE-301 trial will be time to conversion of SVT within 30 minutes following initial study drug administration, with a target p-value of less than 0.05 for each trial. Milestone expects to report data from the RAPID trial in late 2021/early 2022. The RAPID and completed NODE-301 trials could potentially serve to fulfill the efficacy requirement for a future New Drug Application (NDA) for etripamil in patients with PSVT.
  • Raised $51.7 Million in Public Offering.
     In October 2020, Milestone announced the closing of an underwritten public offering of 5,095,897 of its common shares and, to certain investors in lieu thereof, pre-funded warrants to purchase 4,761,903 of its common shares at an exercise price of $0.01 per share. The public offering price of each common share was $5.25 and the public offering price of each pre-funded warrant was $5.24 per underlying share. Total gross proceeds to Milestone were approximately $51.7 million before deducting underwriting discounts and offering expenses.
  • Recent Changes to Board of Directors. In September 2020, Milestone announced the appointment of highly accomplished industry veterans Lisa Giles and Robert Wills to its Board of Directors. In addition, the Company today announced that Dr. Wills will replace Paul R. Edick as Chairman of the Board of Directors. Mr. Edick will be stepping down from the Board, effective January 1, 2021, to focus on his role as Chief Executive Officer at Xeris Pharmaceuticals and their recent product launch.

Mr. Oliveto added, “On behalf of the entire Board of Directors, I would like to thank Paul for his insights and contributions over the last two years. We wish him the very best of luck in all of his future endeavors.”

Third Quarter 2020 Financial Results

  • As of September 30, 2020, Milestone had cash, cash equivalents, and short-term investments of $102.9 million, 24.7 million shares outstanding and 6.7 million pre-funded warrants outstanding.
  • Research and development expenses for the third quarter of 2020 were $8.2 million compared with $9.5 million for the prior year period. For the nine months ended September 30, 2020, research and development expenses were $28.7 million compared with $27.8 million for the prior year period. The increase for the nine-month period ending September 30, 2020 reflects increased clinical development costs supporting Milestone’s Phase 3 clinical trials and efforts in developing a clinical trial pathway for etripamil.
  • General and administrative expenses for the third quarter of 2020 were $3.0 million compared with $2.1 million for the prior year period. For the nine months ended September 30, 2020, general and administrative expenses were $8.6 million compared with $4.7 million for the prior year period. The increase in the nine-month period ending September 30, 2020 reflects increasing insurance costs, as well as additional professional fees and head count to support the compliance requirements of being a public company.
  • Commercial expenses for the third quarter of 2020 were $0.9 million compared with $2.1 million for the prior year period. For the nine months ended September 30, 2020, commercial expense was $4.6 million compared with $6.4 million for the prior year period. The decrease in expenses in the nine-month period ending September 30, 2020 reflects efforts in reducing operating expenses affecting primarily pre-commercialization activities as Milestone focused its efforts on an optimized clinical development pathway for etripamil.
  • For the third quarter of 2020, operating loss was $12.1 million compared to $13.7 million in 2019. For the nine months ended September 30, 2020, Milestone’s operating loss was $41.9 million compared to $39.0 million in the prior year period.

About Paroxysmal Supraventricular Tachycardia

PSVT is a rapid heart rate condition characterized by intermittent episodes of SVT that start and stop suddenly and without warning. Episodes of SVT are often associated with symptoms including palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting, and anxiety. Certain calcium channel blockers have long been approved for the treatment of PSVT as well as other cardiac conditions. However, calcium channel blockers approved for the termination of SVT episodes must be administered intravenously under medical supervision, usually in an emergency department or other acute care setting.

About Etripamil

Etripamil, the Company’s lead investigational product, is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which has the potential to shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials underway in PSVT, and plans to commence a Phase 2 proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “potential,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential of etripamil as a promising therapy for PSVT patients, the design, progress, timing, scope and results of the RAPID trial , Milestone’s expectations regarding an NDA filing and potential FDA approval for etripamil, Milestone’s ability to execute on the remainder of the PSVT program and Milestone’s plans to study etripamil in atrial fibrillation patients. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation, enrollment, completion and evaluation of clinical trials, and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, as well as risks related to pandemics and public health emergencies, including those related to COVID-19, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission, including in its quarterly report on Form 10-Q for the quarter ended September 30, 2020, under the caption “Risk Factors.” Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 


INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPRENHENSIVE LOSS

(Unaudited)


‘000


‘000

[In US dollars]

Three months ended September 30,

Nine months ended September 30,


2020

2019


2020

2019

$

$

$

$


Operating expenses

Research and development, net of tax credits


8,228

9,545


28,722

27,836

General and administrative


2,952

2,104


8,611

4,725

Commercial


905

2,076


4,615

6,428


Loss from operations


(12,085)

(13,725)


(41,948)

(38,989)

Interest income, net of bank charges


89

821


630

1,993


Loss and comprehensive loss before income taxes


(11,996)

(12,904)


(41,318)

(36,996)


Income tax recovery


(17)

(73)


(17)

(55)


Net loss and comprehensive loss for the period


(11,979)

(12,831)


(41,301)

(36,941)


Weighted average number of shares outstanding,


      basic and diluted


29,774,065

24,490,742


26,329,581

12,848,974


Net loss per share, basic and diluted

$                (0.40)

$                (0.52)

$                (1.57)

$                (2.87)

 


INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

[In US dollars]


‘000


September 30,

December 31,


2020

2019


$

$


ASSETS


Current Assets

Cash and Cash Equivalents 


102,910

119,818

Prepaid expenses and other current assets


4,509

2,681


Total current assets


107,419

122,499

Operating lease right of use asset


1,045

524

Property and equipment 


333

405


Total assets


108,797

123,428


LIABILITIES


Current liabilities

Accounts payable and accrued liabilities


5,647

7,997

Operating lease liabilities


234

330


Total current liabilities


5,881

8,327

Operating lease liabilities


718

184


Total liabilities


6,599

8,511


Shareholders’ Equity

Share capital

Common shares, no par value, unlimited shares authorized,

24,727,000 shares issued at September 30, 2020 and 
24,505,748 shares issued at December 31, 2019


226,758

226,245

Pre-funded Warrants – 6,655,131 issued at September 30, 2020


24,770

Additional paid in Capital


7,104

3,805

Cumulative translation adjustment


(1,634)

(1,634)

Accumulated Deficit


(154,800)

(113,499)


Total shareholders’ equity


102,198

114,917


Total liabilities and shareholders’ deficit


108,797

123,428

 

Contact:

David Pitts

Argot Partners
212-600-1902
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-clinical-and-corporate-update-301172505.html

SOURCE Milestone Pharmaceuticals, Inc.

Maverix Announces Record Third Quarter 2020 Results

PR Newswire

VANCOUVER, BC, Nov. 13, 2020 /PRNewswire/ – Maverix Metals Inc. (“Maverix” or the “Company”) (NYSE American: MMX) (TSX: MMX) is pleased to announce its operating and financial results for the third quarter ended September 30, 2020.

All amounts are in U.S. dollars unless otherwise indicated.


Third Quarter 2020 Highlights

  • Record revenue of $14.9 million;
  • Record cash flow from operating activities, excluding changes in non-cash working capital, of $10.8 million1;
  • Record total attributable gold equivalent ounces sold of 7,7971;
  • Average cash cost per attributable gold equivalent ounce sold of $195, resulting in a cash operating margin of 90% or $1,710 per ounce1;
  • Record net income of $14.4 million and adjusted net income of $5.3 million1;
  • Announced the acquisition of a portfolio of 11 gold royalties from Newmont Corporation (“Newmont”) for upfront consideration of $75 million and potential future contingent payments of up to a maximum of $15 million; and
  • Repaid $41 million of the outstanding balance on Maverix’s revolving credit facility.

Dan O’Flaherty, CEO of Maverix, commented, “Our stellar third quarter results once again demonstrate the quality and diversification of our royalty and stream portfolio. We are also excited to have recently completed the accretive acquisition of a second royalty portfolio from our largest shareholder, Newmont, which further enhances our portfolio.”


Summary of Quarterly Results


Quarter Ended

(in thousands of USD, except for Attributable Gold Equivalent ounce and per share amounts)


September 30, 2020


September 30, 2019


Statement of Income and Comprehensive Income

Royalty revenue

$

8,689

$

6,469

Sales

$

6,162

$

4,085

Total revenue

$

14,851

$

10,554

Cash flow from operating activities

$

13,792

$

6,034

Net income

$

14,437

$

1,803

Basic earnings per share

$

0.11

$

0.02

Dividends declared per share

$

0.01

$

0.00


Non-IFRS and Other Measures
1

Adjusted net income

$

5,336

$

1,797

Total Attributable Gold Equivalent ounces sold

7,797

7,208

Average realized gold price per Total Attributable Gold Equivalent ounce sold

$

1,905

$

1,464

Average cash cost per Total Attributable Gold Equivalent ounce sold

$

195

$

169

Cash flow from operating activities, excluding changes in non-cash working capital

$

10,841

$

7,655

For complete details please refer to the Condensed Consolidated Interim Financial Statements and associated Management Discussion and Analysis for the quarter ended September 30, 2020, available on SEDAR (www.sedar.com), EDGAR (www.sec.gov) or on Maverix’s website (www.maverixmetals.com).

Maverix reestablishes guidance and now expects attributable gold equivalent ounces of 26,000 to 27,000 for the year ending December 31, 2020, with approximately 99% of expected revenue derived from gold and silver at a cash operating margin of approximately 90%.

To listen to Maverix’s President, Ryan McIntyre, discuss the record-setting third quarter results please use this link:
MMX Q3 2020 Results 


Asset Portfolio Updates

Morondo (2% NSR Royalty)

On October 26th, Montage Gold Corp. (“Montage”) announced that, following the successful completion of its C$30 million initial public offering in late October, it commenced an aggressive 50,000 metre resource expansion drill program at its Morondo project in Côte d’Ivoire. Montage expects to release an updated inferred mineral resource and complete a PEA in the first quarter of 2021.

For more information, please refer to www.montagegoldcorp.com and see the news release dated October 26, 2020.

Mother Lode (1% – 2% NSR Royalty)

On October 7th, Corvus Gold Inc. (“Corvus”) announced the results of a Preliminary Economic Assessment (“PEA”) for its Mother Lode project in southwest Nevada. The results indicate robust economics at a gold price of $1,500 per ounce with pre-tax free cash flow of $564 million and a post-tax net present value of $303 million (using a 5% discount rate) and an internal rate of return of 23%. The Mother Lode project is modeled as a large, open-pit, with a biological oxidation mill to treat the higher-grade sulphide mineralization and a heap leach pad for treatment of oxide mineralization capable of producing 171,000 ounces of gold per year during its projected 8 year mine life.

For more information, please refer to www.corvusgold.com and see the news release dated October 7, 2020.

Hasbrouck-Three Hills (1.25% NSR Royalty)

On November 5th, West Vault Mining Inc. (“West Vault”) announced receipt from the Bureau of Land Management of a Decision Record and Finding of No Significant Impact for the Hasbrouck mine, signifying the completion of federal permitting, and the final major permitting step to allow construction. The Hasbrouck mine is planned as phase two of the Hasbrouck gold project, with phase 1 being the fully permitted Three Hills mine. The Hasbrouck gold project is one of only a few shovel-ready gold projects in the southwest United States.

For more information, please refer to www.westvaultmining.com and see the news release dated November 5, 2020.

Moss (100% Silver Stream)

On October 7th, Northern Vertex Mining Corp. (“Northern Vertex”) announced record production of 14,673 gold equivalent ounces at the Moss mine for the quarter ended September 30, 2020. Northern Vertex also announced, on October 15, 2020, that additional high-grade gold and silver drill results have been received from its multi-phase resource expansion program at the mine, specifically from the Ruth Vein and the surrounding area. These positive drill results achieved from the Ruth Vein and its proximity to the Moss Vein open pit makes it an important target for further testing for the possibility of additional resources, pit expansion and mine life extension.

For more information, please refer to www.northernvertex.com and see the Northern Vertex news releases dated October 7, 2020 and October 15, 2020.

Beta Hunt (4.75% Royalty on Gold and 1.5% Royalty on Nickel)

On September 8th and 10th, Karora Resources Inc. (“Karora”) announced discoveries of new high-grade gold and nickel mineralization at Western Flanks. As a result of the recent exploration success, Karora announced an increase of its 2020 exploration expenditures to A$15 million at its consolidated Western Australia assets. Furthermore, on November 2nd, Karora announced the discovery of approximately 2,000 ounces of coarse gold in the A Zone shear. Karora expects to release an updated mineral reserve and resource estimate during the fourth quarter of 2020.

For more information, please refer to www.karoraresources.com and see the Karora news releases dated September 8, 2020, September 10, 2020, and November 2, 2020.


Dividend

The quarterly cash dividend of $0.01 per common share will be paid on or about December 15, 2020, to shareholders of record as of the close of business on November 30, 2020.

This dividend is designated as an “eligible dividend” for the purposes of the Income Tax Act (Canada). Dividends paid by Maverix to shareholders outside Canada (non-resident investors) will be subject to Canadian non-resident withholding taxes. The declaration, timing, amount and payment of future dividends remains at the discretion of Maverix’s Board of Directors.


1 Maverix has included certain performance measures in this news release that do not have any standardized meaning prescribed by International Financial Reporting Standards (“IFRS”) including adjusted net income, total Attributable Gold Equivalent ounces sold, average realized gold price per Attributable Gold Equivalent ounce sold, average cash cost per Attributable Gold Equivalent ounce sold, cash operating margin and cash flow from operating activities, excluding changes in non-cash working capital. Adjusted net income is calculated by excluding the effects of other income/expenses, impairment charges, gains/(losses) on sale of royalty and streams and unusual non-recurring items. The Company believes that adjusted net income is a useful measure of the Company’s performance because it adjusts for items which may not relate to or have a disproportionate effect on the period in which they are recognized, impact the comparability of our core operating results from period to period, are not always reflective of the underlying operating performance of our business and/or are not necessarily indicative of future operating results. The Company’s royalty revenue and silver sales are converted to an Attributable Gold Equivalent ounce basis by dividing the royalty revenue and silver sales for a period by the average gold price based on the LBMA Gold Price PM Fix per ounce for the same respective period. These Attributable Gold Equivalent ounces when combined with the gold ounces sold from the Company’s gold streams (individually and collectively referred to as “Attributable Gold Equivalent”) equal total Attributable Gold Equivalent ounces sold. Average realized gold price per Attributable Gold Equivalent ounce sold is calculated by dividing the total revenue by the Attributable Gold Equivalent ounces sold. Average cash cost per Attributable Gold Equivalent ounce sold is calculated by dividing the total cost of sales, less depletion, by the Attributable Gold Equivalent ounces sold. In the precious metals mining industry, these are common performance measures but do not have any standardized meaning. Cash operating margin is calculated by subtracting the average cash cost per Attributable Gold Equivalent ounce sold from the average realized gold price per Attributable Gold Equivalent ounce sold. The Company presents cash operating margin as it believes that certain investors use this information to evaluate the Company’s performance in comparison to other companies in the precious metal royalty and streaming sector who present results on a similar basis. The Company has also used the non-IFRS measure of operating cash flows excluding changes in non-cash working capital. This measure is calculated by adding back the decrease or subtracting the increase in changes in non-cash working capital to or from cash provided by (used in) operating activities. The presentation of these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Other companies may calculate these non-IFRS measures differently.


Qualified Person

Brendan Pidcock, P.Eng., is Vice President Technical Services for Maverix, and a qualified person under National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical disclosure contained in this press release.


About Maverix

Maverix is a gold-focused royalty and streaming company with a globally diversified portfolio of over 100 assets. Maverix’s mission is to increase per share value by acquiring precious metals royalties and streams. Its shares trade on both the NYSE American and the TSX under the ticker “MMX”.

Cautionary statements to U.S. investors

The financial information included or incorporated by reference in this press release or the documents referenced herein has been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, which differs from US generally accepted accounting principles (“US GAAP”) in certain material respects, and thus are not directly comparable to financial statements prepared in accordance with US GAAP.

Information contained or referenced in this press release or in the documents referenced herein concerning the properties, technical information and operations of Maverix has been prepared in accordance with requirements and standards under Canadian securities laws, which differ from the requirements of US securities laws. The terms “mineral resource”, “measured mineral resource”, “indicated mineral resource” and “inferred mineral resource” used in this press release or in the documents incorporated by reference herein are mining terms as defined in accordance with NI 43-101 under guidelines set out in the Definition Standards for Mineral Resources and Mineral Reserves adopted by the Canadian Institute of Mining, Metallurgy and Petroleum Council on 11 December 2005. While the terms “mineral resource”, “measured mineral resource”, “indicated mineral resource” and “inferred mineral resource” are recognized and required by Canadian securities laws, they are not recognized by SEC standards and normally are not permitted to be used in reports filed with the SEC. Investors are cautioned not to assume that all or any part of the disclosed mineral resource estimates will ever be confirmed or converted into reserves that meet the definitions used by the SEC.  Disclosure of contained ounces are or may be permitted disclosure under regulations applicable to Maverix; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in-place tonnage and grade without reference to unit of production measures. Accordingly, certain information contained in this press release or in the documents incorporated by reference herein concerning descriptions of mineralization and mineral resources under these standards may not be comparable to similar information made public by US companies subject to reporting and disclosure requirements of the SEC.

Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, statements with respect to Maverix’s financial guidance, attributable gold equivalent ounce guidance, financial outlook, the payment of Maverix’s dividend, proposed plans for acquiring additional stream and royalty interests and the potential of such streams and royalty interests to provide returns, corporate and operational updates at mines, properties, projects or mining operations that Maverix holds an interest in and the completion of expansion and or construction phases at the mines or properties that Maverix holds an interest in. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the impact of general business and economic conditions; the absence of control over mining operations from which Maverix will purchase gold and other metals or from which it will receive royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined; accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties or interruptions in operations; problems inherent to the marketability of gold and other metals; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; industry conditions, including fluctuations in the price of the primary commodities mined at such operations, fluctuations in foreign exchange rates and fluctuations in interest rates; government entities interpreting existing tax legislation or enacting new tax legislation in a way which adversely affects Maverix; stock market volatility; regulatory restrictions; liability, competition, the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on Maverix’s business, operations and financial condition, loss of key employees, as well as those risk factors discussed in the section entitled “Risk Factors” in Maverix’s annual information form dated March 23, 2020 available at www.sedar.com. Maverix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. Maverix undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

Technical and third-party information

The disclosure herein and relating to properties and operations on the properties in which Maverix holds royalty, stream or other interests is based on information publicly disclosed by the owners or operators of these properties and information/data available in the public domain as at the date hereof, and none of this information has been independently verified by Maverix. Specifically, as a royalty or stream holder, Maverix has limited, if any, access to properties included in its asset portfolio. Additionally, Maverix may from time to time receive operating information from the owners and operators of the properties, which it is not permitted to disclose to the public. Maverix is dependent on, (i) the operators of the properties and their qualified persons to provide information to Maverix, or (ii) on publicly available information to prepare disclosure pertaining to properties and operations on the properties on which Maverix holds royalty, stream or other interests, and generally has limited or no ability to independently verify such information. Although Maverix does not have any knowledge that such information may not be accurate, there can be no assurance that such third-party information is complete or accurate. Some information publicly reported by operators may relate to a larger property than the area covered by Maverix’s royalty, stream or other interest. Maverix’s royalty, stream or other interests often cover less than 100% and sometimes only a portion of the publicly reported mineral reserves, mineral resources and production of a property.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/maverix-announces-record-third-quarter-2020-results-301172551.html

SOURCE Maverix Metals Inc.

Small groups. Big screens. – Cineplex introduces ‘Private Movie Nights’

Canada NewsWire

Movie-Lovers Can Reserve an Entire Cineplex Auditorium Starting at Just $125

Enjoy a Safe Big Screen Experience with Up to 20 Guests – Just in Time for the Holidays!

TORONTO, Nov. 13, 2020 /CNW/ – (TSX: CGX) – Do you have cabin fever? We’ve got you covered! Cooped up Canadians can continue enjoying the magic of movie theatres with friends and family this holiday season. Cineplex, one of Canada’s leading entertainment and media companies, is announcing the launch of ‘Private Movie Nights’ – a new private screening offering that provides Canadians a fun and safe way to catch their favourite flick on the big screen, day or night.

Just in time for the holidays, Canadian movie-lovers can get out of the house to experience amazing sound, giant screens, incomparable cinematic experiences, and indulge in a delicious selection of snacks! Starting at just $125 for groups of up to 20 guests, these unique and memorable movie experiences include a private auditorium rental and the choice of more than 1,000 movie titles. Whether you are celebrating date night with a big screen viewing of Love Actually or planning a family holiday movie matinee with your little ‘Whos’ to see The Grinch, Cineplex has film titles for everyone including new and current releases, holiday favourites and all-time classics.

“Going to the movies is a holiday tradition for so many Canadians, and we are delighted to offer a safe and welcoming place for families and friends to keep their traditions alive through the magic of the movie theatre experience,” said Ellis Jacob, President and CEO, Cineplex. “Health and safety remain our top priority today and throughout this entire pandemic, and I couldn’t be prouder of how hard our local theatre teams have worked to keep Canadians safe since our reopening. ‘Private Movie Nights’ are an affordable way for families, friends, and other groups to safely gather and celebrate the season.”

Canadians across the country – COVID-19 government restrictions permitting – can book ‘Private Movie Nights’ screenings by visiting Cineplex’s dedicated web page. The ability to book an auditorium through Cineplex.com instantly in just three clicks will be available to movie-lovers in the coming days.

Cineplex guest survey data shows that Canadians feel overwhelmingly safe in the theatre environment as well, with a 93 per cent satisfaction rate on auditorium health and safety, and a 95 per cent satisfaction rate on overall experience. Since reopening in late-June, Cineplex has proudly hosted thousands of film screenings with no reported or confirmed transmissions of COVID-19 at any of its locations. In fact, there have been no outbreaks traced to movie theatres anywhere in the world, according to the Global Cinema Federation.

Private bookings and event rentals are also available at Cineplex’s locations of Playdium and The Rec Room – COVID-19 restrictions permitting – including use of the entire space, unlimited play on games, and dedicated staff for your time there. Click here to learn more about safety protocols at Cineplex theatres, The Rec Room and Playdium locations. 

About Cineplex
Cineplex (TSX: CGX) is a top-tier Canadian brand that operates in the film entertainment and content, amusement and leisure, and media sectors. As a leading entertainment and media company, Cineplex welcomes millions of guests annually through its circuit of theatres and location-based entertainment (“LBE”) venues across the country. In addition to being Canada’s largest and most innovative film exhibitor, Cineplex also operates successful businesses in digital commerce (CineplexStore.com), food service, alternative programming (Cineplex Events), cinema media (Cineplex Media), digital place-based media (Cineplex Digital Media “CDM”) and amusement solutions (Player One Amusement Group “P1AG”). Additionally, Cineplex operates an LBE business through Canada’s newest destinations for ‘Eats & Entertainment’ (The Rec Room), and entertainment complexes specifically designed for teens and families (Playdium). Cineplex is a joint venture partner in SCENE, Canada’s largest entertainment loyalty program.

Proudly recognized as having one of the country’s Most Admired Corporate Cultures, Cineplex employs approximately 13,000 people in its offices across Canada and the United States. To learn more visit Cineplex.com or download the Cineplex App.

SOURCE Cineplex

MAV Beauty Brands Reports Third Quarter 2020 Financial Results

Canada NewsWire

  • Total revenue up 12% year-over-year to $31.7 million and revenue from North America increases 15% to $30.0 million
  • Company reports record Adjusted EBITDA of $8.7 million, Adjusted Free Cash Flow of $4.4 million
  • Net income increases 21% year-over-year to $3.6 million and earnings per share (basic) increases 25% to $0.10

VAUGHAN, ON, Nov. 13, 2020 /CNW/ – MAV Beauty Brands Inc. (“MAV Beauty Brands” or the “Company”) (TSX: MAV), a global personal care platform, today announced its financial results for the three and nine months ended September 30, 2020. Unless otherwise indicated, all amounts are expressed in U.S. dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures (see “Non-IFRS Measures” below).

“We are pleased to report another quarter of strong results in 2020, particularly in light of the extraordinary operating environment. The results were highlighted by double-digit revenue growth, record Adjusted EBITDA, and robust free cash flow,” said Tim Bunch, President & CEO of MAV Beauty Brands. “The third-quarter results add to our strong year-to-date performance across these key financial measures. This speaks to the great efforts of our team and the resilience of the platform, which is increasingly diversified across brands, consumers, segments, and channels. These attributes serve us well in periods of uncertainty, mitigating risk while allowing us to benefit from shifting consumer preferences. The growth of our e-commerce business continues to be a bright spot in 2020, with sales once again more than doubling year over year.”  

Selected Financial Highlights(1)(2)  


(in thousands of US dollars except per share amounts) (unaudited)


Q3 2020


Q3 2019


% Change


YTD 2020


YTD 2019


% Change


Revenue

31,741

28,368

11.9

92,761

77,708

19.4


Gross profit

15,748

14,125

11.5

44,668

38,440

16.2


Net income (loss) for the period

3,559

2,939

21.1

6,398

5,261

21.6


Earnings per share (basic)

0.10

0.08

25.0

0.17

0.14

21.4


Adjusted EBITDA

8,700

8,476

2.6

25,073

20,986

19.5


Cash flow from operations

7,010

5,917

18.5

16,291

13,447

21.1


Adjusted Free Cash Flow

4,380

5,634

-22.3

8,601

6,749

27.4


Adjusted Net Income 

4,179

3,842

8.8

11,837

9,077

30.4


Adjusted Earnings per Share (diluted)

0.098

0.096

3.0

0.28

0.22

25.0


(1)


See “Non-IFRS Measures”


(2)


Basic Earnings per Share calculation does not include the impact of 2,463,963 common shares of the Company issuable upon the exchange of the units issued as part of The Mane Choice acquisition

Q3 2020 Financial Review 

Revenue for Q3 2020 grew by 12% over Q3 2019 to $31.7 million. Growth in the quarter reflected our proven ability to accretively acquire businesses such as The Mane Choice (in November 2019), tempered by COVID-19 headwinds which reduced retail foot traffic and temporarily reduced  promotional activity at key retail partners as many of these retailers re-allocated promotional shelf space to other COVID-related essential items. Revenue from North America (which represents approximately 95% of total revenue) was $30.0 million in Q3 2020, up 15% from $26.0 million in Q3 2019.

For the fiscal year to date, revenue grew both organically and inorganically by 19% over 2019 to $92.8 million, reflecting the same factors mentioned above. In general, performance matched our objective of coupling accretive M&A with organic growth that outpaces the overall category. Despite the uncertain and extraordinary environment in retail in 2020, we believe this revenue growth demonstrates the value of our platform.

Over the past year, we continued to leverage our operating platform to build our brands and drive organic growth, using a four-pronged strategy: 1) expand the distribution footprint; 2) introduce winning innovation; 3) amplify the brands; 4) drive efficiencies. Over the past year, we have effectively executed on each of the strategies. We have secured new distribution for each of our brands and accelerated e-commerce sales; expanded our skin care products through innovation; greatly increased brand impressions through our marketing efforts; and generated efficiencies in cost of goods sold.

Q3 2020 gross profit increased 12% year over year to $15.7 million, and Q3 2020 gross profit margin, at 49.6%, was similar to the prior year period (49.8%). We expect some variability in gross margin quarter to quarter based on product mix and promotional decisions, which impact trade spend. Importantly, we have been successful at generating product cost savings over the past year which has allowed for steady margin improvements, as reflected in our year-to-date gross margin of 51% compared to 49% in the prior year.

Excluding share-based compensation charges of $0.4 million, Q3 2020 selling and administrative expense was $6.9 million, or 22% of sales, compared with $5.6 million, or 20% of sales, in the same period last year, excluding $0.7 million of share-based compensation charges in Q3 2019. While higher than the prior year, primarily as a result of the addition of The Mane Choice, selling and administrative expense has remained relatively constant in 2020.

Q3 2020 Adjusted EBITDA increased by 3% to a record $8.7 million (27.4% of revenue), from Adjusted EBITDA of $8.5 million in Q3 2019 (29.9% of revenue) (see “Non-IFRS Measures” below). Adjusted EBITDA margin in the current period was consistent with the first and second quarters of 2020. In Q3 2020, the Company reported net income of $3.6 million, up 21% from $2.9 million in Q3 2019, and Adjusted Net Income increased by 9% to $4.2 million, compared with Adjusted Net Income of $3.8 million in Q3 2019, reflecting the factors discussed above (see “Non-IFRS Measures” below).

Q3 2020 cash flow from operations was $7.0 million, up 18% from the prior year. In addition, the current quarter reflects increased working capital investment, primarily due to higher receivables as a result of increased revenues, and higher inventory. As a result, the Company generated Adjusted Free Cash Flow of $4.4 million in Q3 2020, compared with $5.6 million in Q3 2019 (see “Non-IFRS Measures” below). On a Pro Forma basis, including the results of The Mane Choice for the trailing 12 months, the Net Debt-to-Adjusted EBITDA ratio was 3.9 times, compared with 4.0 times at the end of Q2 2020 (see “Non-IFRS Measures” below). 

Q3 2020 Financial Statements and Management’s Discussion and Analysis

The Company’s unaudited consolidated interim financial statements for the three- and nine-month periods ended September 30, 2020 and Management’s Discussion and Analysis are available under the Company’s profile on SEDAR at www.sedar.com and on MAV Beauty Brands’ investor relations website at investors.mavbeautybrands.com.

Annual General Meeting

This year, to mitigate risks to the health and safety of our communities, shareholders, employees and other stakeholders resulting from the COVID-19, the Company will hold its annual general meeting of shareholders in a virtual-only format on November 13 at 2:00 p.m. EST. The event can be accessed from MAV Beauty Brands’ investor relations website at investors.mavbeautybrands.com or at https://web.lumiagm.com/264999089.

Conference Call & Webcast

MAV Beauty Brands will host a conference call to discuss its fiscal 2020 third quarter financial results at 8:30 a.m. EST on November 13, 2020. The call will be hosted by Tim Bunch, President & CEO, and Judy Adam, CFO. To participate in the call, dial (416) 764-8659 or (888) 664-6392 (using the conference ID 58878160). The audio webcast can be accessed at investors.mavbeautybrands.comhttps://bit.ly/2mutHer. Listeners should access the webcast or call 10-15 minutes before the start time to ensure they are connected.

About MAV Beauty Brands (TSX:MAV)

MAV Beauty Brands is a global personal care platform focused on acquiring great independent brands and helping these brands to scale and win market share. We have built an operating platform to build brands through expanded distribution, innovation, and marketing. Today, we have a diversified portfolio of four complementary personal care brands – Marc Anthony True Professional, Renpure, Cake Beauty and The Mane Choice – offering premium quality hair care, body care and beauty products. These products are sold in over 30 countries around the world and in more than 100 of the world’s largest retailers.

Non–IFRS Measures 

This press release makes reference to certain non–IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non–IFRS measures including “Adjusted EBITDA”, “Adjusted Net Income”, “Free Cash Flow”, “Adjusted Free Cash Flow” and “Net debt-to-Adjusted EBITDA”. These non–IFRS measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non–IFRS measures in the evaluation of issuers. Our management also uses non–IFRS measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and to determine components of management compensation. Definitions and reconciliations of non-IFRS measures to the relevant reported measures can be found in our MD&A. Such reconciliations can also be found in this press release under the headings “Q3 2020 Compared to Q3 2019”.

“Adjusted EBITDA” represents, for the applicable period, EBITDA as adjusted to add back or deduct, as applicable, certain expenses, costs, charges or benefits incurred in such period which in management’s view are not indicative of continuing operations, including: (i) integration, restructuring, and other costs; (ii) shareholder fees and related costs; (iii) purchase accounting adjustments; (iv) share–based compensation; and (v) unrealized foreign exchange (gain) loss.

“Adjusted Free Cash Flow” is calculated as free cash flow adjusted to add back acquisition related costs which are included in cash provided by operating activities. We believe Adjusted free cash flow is a useful measure to assess the Company’s ability to repay debt, finance strategic business acquisitions and investments, pay dividends and repurchase shares. It also facilitates period-to-period comparisons.

Adjusted Net Income” represents, for the applicable period, net income (loss) and comprehensive income (loss) as adjusted to add back or deduct, as applicable, certain expenses, costs, charges or benefits incurred in such period which in management’s view are not indicative of continuing operations, including: (i) integration, restructuring, and other costs; (ii) shareholder fees and related costs; (iii) purchase accounting adjustments; (iv) share–based compensation; (v) unrealized foreign exchange (gain) loss; and (vi) tax impacts of the aforementioned adjustments (based on annual effective tax rate).

EBITDA” represents net income (loss) and comprehensive net income (loss) for the period before: (i) income tax (recovery) expense; (ii) interest; and (iii) amortization and depreciation.

Free Cash Flow” represents, for the applicable period, cash provided by operating activities less cash used to purchase property and equipment. Free cash flow is a key metric that measures the Company’s ability to repay debt, finance strategic business acquisitions and investments, pay dividends and repurchase shares.

“Net debt and Net debt-to-Adjusted EBITDA” net debt is calculated as long-term debt before unamortized deferred financing costs less cash as reported in the consolidated statements of financial position. Net debt-to-Adjusted EBITDA is calculated as net debt divided by Adjusted EBITDA for the four trailing quarters. Net debt is an important measure as it reflects the principal amount of debt owing by the Company as at a particular date. Net debt-to-Adjusted EBITDA is an important measure of the Company’s liquidity. References to such calculation on a pro forma basis gives effect to the acquisition of The Mane Choice as if it occurred on January 1, 2019.

In addition, pro forma information regarding The Mane Choice should not be considered to be what the actual financial position or other results of operations of the Company would have necessarily been had The Mane Choice acquisition been completed, as, at, or for the periods stated.

Forward-Looking Information
Certain information in this press release, including statements relating to the Company’s ability to navigate the business environment during the COVID-19 pandemic. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by MAV Beauty Brands as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the Company’s Annual Information Form dated on or about March 30, 2020 for the year ended December 31, 2019 and the Company’s other periodic filings made available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect MAV Beauty Brands; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and MAV Beauty Brands expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Q3 2020 Compared to Q3 2019


(in thousands of US dollars) (unaudited)


Q3 2020


Q3 2019


$ Change


% Change


Consolidated statements of operations:


Revenue


31,741


28,368


3,373


11.9%

Cost of sales


15,993


14,243


1,750


12.3%

Gross profit


15,748


14,125


1,623


11.5%


Expenses

Selling and administrative


7,302


6,276


1,026


16.3%

Amortization and depreciation


1,060


884


176


19.9%

Interest and accretion


1,762


1,787


(25)


-1.4%

Foreign exchange loss


141


190


(49)


-25.8%

Integration, restructuring, and other


437


395


42


10.6%


10,702


9,532


1,170


12.3%

Income before income taxes


5,046


4,593


453


9.9%


Income tax expense (recovery)

Current


(24)


627


(651)



nmf

Deferred


1,511


1,027


484


47.1%


1,487


1,654


(167)


-10.1%


Net income for the period


3,559


2,939


620


21.1%


EBITDA (1)


7,868


7,264


604


8.3%


Adjusted EBITDA (1)


8,700


8,476


224


2.6%


Adjusted Net Income (1)


4,179


3,842


337


8.8%

(1)

See “Non-IFRS Measures”

 


(in thousands of US dollars) (unaudited)


Q3 2020


Q3 2019


YTD Q3 2020


YTD Q3 2019


Consolidated net income:


3,559


2,939


6,398


5,261

Income tax expense


1,487


1,654


2,667


2,429

Interest and accretion


1,762


1,787


5,580


5,482

Amortization and deprecation


1,060


884


3,128


2,692


EBITDA


7,868


7,264


17,773


15,864

Integration, restructuring, and other

(1)


437


395


3,612


2,186

Purchase accounting adjustments

(2)






2,321



Share-based compensation

(3)


417


642


1,692


2,813

Unrealized foreign exchange loss (gain)


(22)


175


(325)


123


Adjusted EBITDA


8,700


8,476


25,073


20,986


(in thousands of US dollars) (unaudited)


Q3 2020


Q3 2019


YTD Q3 2020


YTD Q3 2019


Consolidated net income:


3,559


2,939


6,398


5,261

Integration, restructuring, and other

(1)


437


395


3,612


2,186

Purchase accounting adjustments

(2)






2,321



Share-based compensation

(3)


417


642


1,692


2,813

Unrealized foreign exchange loss (gain)


(22)


175


(325)


123

Tax impact of the above adjustments


(212)


(309)


(1,861)


(1,306)


Adjusted Net Income


4,179


3,842


11,837


9,077

(1)

Refer to Note 9 to the unaudited condensed consolidated interim financial statements for further details.

(2)

In conjunction with the 2019 Acquisition, the fair value adjustment of inventory as part of the initial purchase price allocation was expensed to cost of sales as the inventories were sold.

(3)

Represents recognition of share-based payments, which have been accounted for as selling and administrative expenses.

 


(in thousands of US dollars) (unaudited)


Q3 2020


Q3 2019


YTD Q3 2020


YTD Q3 2019

Cash provided by operating activities


4,675


5,537


9,715


8,734

Less: purchase of property and equipment


(295)


(164)


(1,114)


(2,246)


Free cash flow


4,380


5,373


8,601


6,488

Add: Acquisition related costs




261




261


Adjusted free cash flow


4,380


5,634


8,601


6,749

(1)

See “Non-IFRS Measures”

 

SOURCE MAV Beauty Brands Inc.